

1. General data

Boor, Peter, Priv.-Doz. Dr. med., PhD

***23.04.1979 (m)**

Institute of Pathology
University Hospital Aachen, RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 85227
Fax: ++49 (0)241-80 82439
E-mail: pboor@ukaachen.de



Resident and Group leader at the Institute of Pathology

2. Scientific education

05/2004	Final medical examinations
2001 - 2002	Medical School of the RWTH University, Aachen, Germany
1997 - 2004	Medical School of the Comenius University, Bratislava, Slovakia

3. Academic degrees

04/2012	Habilitation and venia legendi in experimental Pathology (Mentor: Univ.-Prof. Dr. med. Ruth Knüchel-Clarke)
10/2009	MD (Dr. med., summa cum laude) in general medicine, Medical School of the RWTH University Aachen (Mentor: Prof. Dr. Jürgen Floege)
10/2008	PhD in clinical pharmacology at the Slovak Medical University, Bratislava, Slovakia (Mentor: Assoc. Prof. Dr. Katarína Šebeková, DSc.)
05/2004	MD (MUDr., summa cum laude) in general medicine, Medical School of the Comenius University in Bratislava, Slovakia (Mentor: Assoc. Prof. Dr. Katarína Šebeková, DSc.)

4. Scientific positions

since 2017	Heisenberg Fellowship funded by the DFG
since 05/2009	Internship at the Institute of Pathology, RWTH University Aachen (Head: Univ.-Prof. MD Ruth Knüchel-Clarke)
02/2015 - 04/2015	Parental leave
01/2008 - 04/2009	Internship at the Department of Clinical and Experimental Pharmacotherapy, Slovak Medical University, Bratislava, Slovakia (Head: Assoc. Prof. MD Martin Gajdoš, PhD)
02/2009	Sabbatical at the Cedars-Sinai Medical Center and Burns and Allen Research Institute, Los Angeles, USA
01/2005 - 12/2007	Postdoctoral Fellow at the Division of Nephrology and Immunology, RWTH University Aachen (Head: Univ.-Prof. Dr. med. Jürgen Floege)
09/2004 - 12/2004	Internship at the Department of Clinical and Experimental Pharmacotherapy, Slovak Medical University, Bratislava, Slovakia (Head: Assoc. Prof. MD Martin Gajdoš, PhD)

5. Other (function in editorial or advisory board, honours and awards)

2016	RWTH Lecturer, award for excellence in teaching and science of the RWTH Aachen University
2014	Liliane Striker Young Investigator Award of the Renal Pathology Society
2011	Doctoral Thesis Award (“Borchers-Plakette”) of the RWTH Aachen University
2010	Young Investigator award, Nexus Meeting “The Kidney and the vascular system”, Kyoto, Japan
2010	Scientific Award (“Friedrich-Wilhelm Preis”) of the RWTH Aachen University

6. Most important publications

- [1] Bábíčková, J., Klinkhammer, B.M., Buhl, E.M., Djudjaj, S., Hoss, M., Heymann, F., Tacke, F., Floege, J., Becker, J.U., **Boor, P. (2017)**: Ultrastructural and functional alterations of peritubular capillaries in progressive renal disease. *Kidney Int*, **91**, 70-85. [Editorial]
- [2]. von Stillfried, S., Apitzsch, J.C., Ehling, J., Penzkofer, T., Mahnken, A.H., Knüchel, R., Floege, J., **Boor, P. (2016)**: Contrast-enhanced CT imaging in patients with chronic kidney disease. *Angiogenesis*, **19**, 525-535.
- [3]. Buhl, E.M., Djudjaj, S., Babickova, J., Klinkhammer, B.M., Folestad, E., Borkham-Kamphorst, E., Weiskirchen, R., Hudkins, K., Alpers, C.E., Eriksson, U., Floege, J., **Boor, P. (2016)**: Role of PDGF-D in healthy and fibrotic kidney. *Kidney Int*, **89**, 848-861. [Highlighted in *Nat Rev Neph* 2016, 12: 257]
- [4] Djudjaj, S., Papisotiriou, M., Bülow, R.D., Wagnerova, A., Lindenmeyer, M.T., Cohen, C.D., Bucala, R., Strnad, P., Goumenos, D.S., Floege, J., **Boor, P. (2016)**: Keratins as Novel Markers of Renal Epithelial Cell Injury. *Kidney Int*, **89**, 792-808. [Editorial & Cover Image]
- [5] Djudjaj, S., Lue, H., Rong, S., Papisotiriou, M., Klinkhammer, B.M., Zok, S., Klaener, O., Braun, G.S., Lindenmeyer, M.T., Cohen, C.D., Bucala, R., Tittel, A.P., Kurts, C., Moeller, M.J., Floege, J., Ostendorf, T., Bernhagen, J., **Boor, P. (2016)**: Macrophage migration inhibitory factor mediates proliferative glomerulonephritis via CD74. *J Am Soc Nephrol*, **27**, 1650-1664.
- [6] Ehling, J., Bábíčková, J., Gremse, F., Klinkhammer, B.M., Baetke, S., Knuechel, R., Kiessling, F., Floege, J., Lammers, T., **Boor, P. (2016)**: Quantitative micro-CT imaging of micro-to-macrovascular dysfunction in progressive kidney diseases. *J Am Soc Nephrol*, **27**, 520–532. [Cover Image]
- [7] **Boor, P.**, Bábíčková, J., Steegh, F., Hautvast, P., Martin, I.V., Djudjaj, S., Nakagawa, T., Ehling, J., Gremse, F., Bücher, E., Eriksson, U., van Roeyen, C.R., Eitner, F., Lammers, T., Floege, J., Peutz-Kootstra, C.J., Ostendorf, T. (2015): Role of PDGF-CC in capillary rarefaction in renal fibrosis. *Am J Pathol*, **185**, 2132-2142.
- [8] Kim, S., Becker, J., Bechheim, M., Kaiser, V., Noursadeghi, M., Fricker, N., Beier, E., Klaschik, S., **Boor, P.**, Hess, T., Hofmann, A., Holdenrieder, S., Wendland, J., Fröhlich, H., Hartmann, G., Nöthen, M., Müller-Myhsok, B., Pütz, B., Hornung, V., Schumacher, J. (2014): Characterizing the genetic basis of innate immune response in TLR4-activated human monocytes. *Nat Commun* **5**, 5236.
- [9] **Boor, P.**, Celec, P., Martin, I.V., Villa, L., Hodossy, R., Klenovicsová, K., Esposito, C., Schäfer, S., Albrecht-Küpper, B., Ostendorf, T., Ostendorf, T., Heidland, A., Šebeková, K. (2011): Peroxisome proliferator-activated receptor- α agonist BAY PP1 attenuates renal fibrosis in rats. *Kidney Int*, **80**, 1182–1197. [Editorial]
- [10] **Boor, P.**, van Roeyen, C.R., Kunter, U., Villa, L., Bücher, E., Hohenstein, B., Hugo, C.P., Eriksson, U., Satchell, S.C., Mathieson, P.W., Eitner, F., Floege, J., Ostendorf, T. (2010): PDGF-CC accelerates glomerular capillary repair in experimental glomerulonephritis. *Am J Pathol*, **177**, 58-69.

Borkham-Kamphorst

1. General data

Borkham-Kamphorst, Erawan, PD., Dr. rer. nat., Dr. med.

***27.04.1957 (f)**

Institute of Molecular Pathobiochemistry, Experimental Gene Therapy
and Clinical Chemistry University Hospital Aachen, RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 88684
Fax: ++49 (0)241-80 3388683
E-mail: ekamphorst@ukaachen.de

Scientific staff (permanent position)



2. Scientific education

01/2017	Habilitation/ <i>Venia legendi</i> for Molecular Pathobiochemistry
2008	Doctor of Medicine (Dr. med.) from the Faculty of Medicine, UKA
2001 – 2004	PhD Study, Faculty of Mathematics, Computer Sciences and Natural Sciences, RWTH-Aachen University, Aachen, Germany
1997 – 2000	Studied Master Program in Medical and Pharmaceutical Research, Faculty of Medicine, and Master Program in Molecular Biology and Biotechnology, Faculty of Science, Free University of Brussels, Belgium
1982 – 1985	Grad. Diploma in Clinical Science and Residency training, Ramahitbodi Hospital, Mahidol University, Bangkok, Thailand
1981 – 1982	Internship, to obtain Practitioner's License, Chulalongkorn University Hospital, Bangkok, Thailand
1975 – 1981	Medical study, Khon Kaen University, Khon Kaen, Thailand

3. Academic degrees

01/2017	Habilitation in Molecular Pathobiochemistry
11/2008	Doctor of Medicine (Dr. med.) with First class honours
03/2005	PhD (Dr. rer. nat.) with Second class honours (sehr gut)
09/2000	Master in Medical and Pharmaceutical Research with distinction
09/1999	M.Sc.in Molecular Biology and Biotechnology with great distinction
08/1985	Board Certificate of Proficiency in Obstetrics and Gynaecology
04/1983	Graduate Diploma in Clinical Science (Obstetrics and Gynaecology)
04/1982	Medical Council Certificate of Practitioner's License
03/1981	Doctor of Medicine Second Class Honours
11/1979	Bachelor of Sciences Second Class Honours

4. Scientific positions

04/2014 – present	Staff Scientist at the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry, UKA (Director Prof. Dr. rer. nat. R. Weiskirchen)
11/2004 – 03/2014	Staff scientific at the Institute of Clinical Chemistry and Pathobiochemistry, UKA (Acting Director: Prof. Dr. rer. nat. R. Weiskirchen)
04/2001 – 11/2004	Promotional research assistant, Institute of Clinical Chemistry and Pathobiochemistry, UKA (Director Prof. Dr. A. M. Gressner)

Borkham-Kamphorst

- 06/1999 – 06/2000 Master thesis at the Dep. of Cellular Immunology of the Flanders Inst. for Biotechnology, University Brussels, (Prof. Dr. P. De Baetselier)
- 11/1994 – 11/1995 Clinical Fellowship at the Centre of Reproductive Medicine, AZ-VUB University Hospital, Brussels (Director Prof. Dr. P. Devroey)
- 05/1994 – 11/1994 Licensed Assistant infertility and IVF unit, Department of OB&GYN, Otto von Guericke University Hospital, Magdeburg, Germany (Director Prof. Dr. med. habil. W. Weise)
- 09/1993 – 04/1994 Clinical Fellowship at Fertility Unit, Dept. of OB&GYN. Leiden University Medical Centre, Leiden, the Netherlands
- 09/1989 – 09/1993 Fulltime obstetrician and gynaecologist, Udonthani Regional Hospital, Udonthani, Thailand (Director Dr. Khunying Ampunt Menakanit)
- 07/1985 – 09/1989 Lecturer at the department of OB&GYN, Faculty of Medicine, Khon Kaen University, Thailand (Dean Prof. Dr. Somporn Pothinam)
- 04/1982 – 07/1985 OB&GYN residency training at Ramathibodi University Hospital, Mahidol University, Bangkok, Thailand (Prof. Dr. Duangduan Kongsak)
- 04/1981 – 04/1982 Internship, Chulalongkorn University Hospital, Bangkok, Thailand

6. Most important publications

- [1] Buhl, E.M., Djudja, S., Babickova, J., Klinkhammer, B.M., Folestad, E., **Borkham-Kamphorst, E.**, Weiskirchen, R., Hudkins, K., Alpers, C.E., Eriksson, U., Floege, J., Boor, P. (2016): The role of PDGF-D in healthy and fibrotic kidneys. *Kidney Int*, **89**, 848-861.
- [2] **Borkham-Kamphorst, E.**, Weiskirchen, R. (2016): The PDGF system and its antagonists in liver fibrosis. *Cytokine Growth Factor Rev*, **28**, 53-61.
- [3] **Borkham-Kamphorst, E.**, Steffen, B.T., Van de Leur, E., Haas, U., Tihaa, L., Friedman, S.L., Weiskirchen, R. (2016): CCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. *Cell Signal*, **28**, 34-42.
- [4] **Borkham-Kamphorst, E.**, Meurer, S. K., Van de Leur, E., Haas, U., Tihaa, L., Weiskirchen, R. (2015): PDGF-D signaling in portal myofibroblasts and hepatic stellate cells proves identical to PDGF-B via both PDGF receptor type α and β . *Cell Signal*, **27**, 1305-1314.
- [5] **Borkham-Kamphorst, E.**, Alexi, P., Tihaa, L., Haas, U., Weiskirchen, R. (2015): Platelet-derived growth factor-D modulates extracellular matrix homeostasis and remodeling through TIMP-1 induction and attenuation of MMP-2 and MMP-9 gelatinase activities. *Biochem Biophys Res Commun*, **457**, 307-313.
- [6] **Borkham-Kamphorst, E.**, Schaffrath, C., Van de Leur, E., Haas, U., Tihaa, L., Meurer, S. K., Nevzorova, Y. A., Liedtke, C., Weiskirchen, R. (2014): The anti-fibrotic effects of CCN1/CYR61 in primary portal MFB are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF- β signaling. *Biochim Biophys Acta*, **1843**, 902-914.
- [7] Cubero, F.J., Singh, A., **Borkham-Kamphorst, E.**, Nevzorova, Y.A., Al Masaoudi, M., Haas, U., Boekschoten, M.V., Gassler, N., Weiskirchen, R., Muller, M., Liedtke, C., Trautwein, C. (2013): TNFR1 determines progression of chronic liver injury in the IKK γ /Nemo genetic model. *Cell Death Differ*, **20**, 1580-1592.
- [8] **Borkham-Kamphorst, E.**, van de Leur, E., Zimmermann, H. W., Karlmark, K. R., Tihaa, L., Haas, U., Tacke, F., Berger, T., Mak, T. W., Weiskirchen, R. (2013): Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis. *Biochim Biophys Acta*, **1832**, 660-673.
- [9] **Borkham-Kamphorst, E.**, Zimmermann, H. W., Gassler, N., Bissels, U., Bosio, A., Tacke, F., Weiskirchen, R., Kanse, S. M. (2013): Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men. *J Hepatol*, **58**, 104-111.
- [10] Martin, I.V., **Borkham-Kamphorst, E.**, Zok, S., van Roeyen, C.R., Eriksson, U., Boor, P., Hittatiya, K., Fischer, H.P., Wasmuth, H.E., Weiskirchen, R., Eitner, F., Floege, J., Ostendorf, T. (2012): Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. *Am J Pathol*, **182**, 107-117.

Brümmendorf

1. General data

Brümmendorf, Tim Henrik, Univ.-Prof. Dr. med. *08.09.1966 (m)

Department of Hematology, Oncology, Hemostaseology and Stem cell transplantation
University Hospital Aachen, RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: +49 (0)241 - 8089806
Fax: +49 (0)241 - 8082449
E-mail: tbruemmendorf@ukaachen.de



Head of the Department, Professor (W3)

2. Scientific education

2005	Board exam in Hematology and Medical Oncology
2003	Board Exam in Internal Medicine
1997-1999	Post-doctoral Research Fellowship (DFG), The Terry Fox Laboratory, Vancouver, Canada (P. Lansdorp)
1995-2003	Residency in Internal Medicine, University Hospital Tübingen
1988-1995	Medical School, University of Heidelberg (1988-90 and 1991-95) and University of Hamburg (1990-91)

3. Academic degrees

2009	Full Professor (W3) and Head, Dept. of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Germany
2007	Appointment as Professor (Apl.), University of Hamburg
2004	Habilitation (venia legend) in Internal Medicine, (Priv.-Doz.), University of Tübingen
1995	Medical Dissertation (M.D., summa cum laude), University of Heidelberg

4. Scientific positions

since 2009	Director, Dept. of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital Aachen, Germany
since 2009	Director Euregional comprehensive Cancer Center Aachen (ECCA)
2007-2009	Deputy Director, University Cancer Center Hamburg (UCCH) and Deputy Head, Department of Hematology and Oncology, University Hospital Eppendorf, Hamburg
1999-2009	Head, Stem Cell and Telomere Biology lab., Dept. Of Hematology/Oncology, University Hospital, Tübingen and University Hospital Eppendorf, Hamburg
1997-99	Post-doctoral Research Fellow (fellowship of the DFG), The Terry Fox Laboratory, Vancouver, Canada (P. Lansdorp)
1991-1995	Doctoral Thesis, Universitätsfrauenklinik (Prof. G. Bastert) and German Cancer Research Center (DKFZ, Dr. Schuhmacher), Heidelberg

Brümmendorf

5. Other (function in editorial or advisory board, honours and awards)

- 2006 Scientific Award of the Interdisciplinary group of laboratory research and flow cytometry (IGLD)
- 2000 Artur Pappenheim Price, German Society of Hematology and Oncology (DGHO)

6. Most important publications

- [1] Schneider, R.K., Schenone, M., Ferreira, M. V., Kramann, R., Joyce, C. E., Hartigan, C., Beier, F., **Brümmendorf, T.H.**, Germing, U., Platzbecker, U., Büsche, G., Knüchel, R., Chen, M. C., Waters, C. S., Chen, E., Chu, L. P., Novina, C. D., Lindsley, R. C., Carr, S. A., Ebert, B. L. (2016): Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. *Nat Med*, **22**, 288-297.
- [2] Weidner, C. I., Lin, Q., Koch, C. M., Eisele, L., Beier, F., Ziegler, P., Bauerschlag, D. O., Jöckel, K. H., Erbel, R., Mühleisen, T. W., Zenke, M., **Brümmendorf, T. H.**, Wagner, W. (2014): Aging of blood can be tracked by DNA methylation changes at just three CpG sites. *Genome Biol*, **15**(2):R24.
- [3] Braig, M., Pällmann N., Preukschas, M., Steinemann, D., Hofmann, W., Gompf, A., Streichert, T., Braunschweig, T., Copland, M., Rudolph, K. L., Bokemeyer, C., Koschmieder, S., Schuppert, A., Balabanov, S., **Brümmendorf, T. H.** (2014): A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. *Leukemia*, **28**, 2028-2039.
- [4] Khoury, H. J., Cortes, J. E., Kantarjian, H. M., Gambacorti-Passerini, C., Baccarani, M., Kim, D. W., Zaritsky, A., Countouriotis, A., Besson, N., Leip, E., Kelly, V., **Brümmendorf, T. H.** (2012): Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. *Blood*, **119**, 3403-3412.
- [5] Schmidt, T., Masouleh, B. K., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., Jonckx, B., De Keersmaecker, K., Tjwa, M., Schenk, T., Fragoso, R., Beel, K., Kleppe, M., Dias, S., Verfaillie, C., Clark, R. E., **Brümmendorf, T. H.**, Vandenberghe, P., Rafii, S., Holyoake, T., Hochhaus, A., Cools, J., Karin, M., Jain, R. K., Carmeliet, G., Dewerchin, M., Carmeliet, P. (2011): Loss or inhibition of stromal-derived PIGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+ leukemia. *Cancer Cell*, **19**, 740-745.
- [6] Gontarewicz, A., Balabanov, S., Keller, G., Colombo, R., Graziano, A., Pesenti, E., Benten, D., Bokemeyer, C., Fiedler, W., Moll, J., **Brümmendorf, T. H.** (2008): Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against Imatinib-resistant BCR-ABL mutations including T315I. *Blood*, **111**, 4355-4364.
- [7] Balabanov, S., Gontarewicz, A., Ziegler, P., Hartmann, U., Kammer, W., Copland, M., Brassat, U., Priemer, M., Hauber, I., Wilhelm, T., Schwarz, G., Kanz, L., Bokemeyer, C., Hauber, J., Holyoake, T. L., Nordheim, A., **Brümmendorf, T. H.** (2007) Hypusination of eukaryotic initiation factor 5A (eIF-5A): a novel therapeutic target in Bcr-Abl-positive leukemias identified by a proteomics approach. *Blood* **109**, 1701-1711.
- [8] **Brümmendorf, T. H.**, Holyoake, T. L., Rufer, N., Barnett, M. J., Schulzer, M., Eaves, C. J., Eaves, A. C., Lansdorp, P. M. (2000): Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. *Blood*, **95**, 1883-1890.
- [9] **Rufer, N.***, **Brümmendorf, T. H.***, Kolvraa, S., Bischoff, C., Christensen, K., Wadsworth, L., Schulzer, M., Lansdorp, P. M. (1999): Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. *J Exp Med*, **190**, 157-167. *both authors contributed equally.
- [10] **Brümmendorf, T. H.**, Dragowska, W., Zijlmans, J. M., Thornbury, G., Lansdorp, P.M. (1998): Asymmetric cell divisions sustain long-term in vitro hematopoiesis from single sorted human fetal liver cells. *J Exp Med*, **188**, 1117-1124.

1. General data

G. Costa, Ivan, Dr. rer. nat.

***20.07.1977 (m)**

IZKF Research Group Bioinformatics
University Hospital Aachen, RWTH Aachen
Pauwelsstr. 19
D-52074 Aachen



Phone: ++49 (0)241-80 20270
E-mail: ivan.costa@rwth-aachen.de

Group Leader

2. Scientific education

2004-2008	Dr. rer. nat. in Bioinformatics, Free University Berlin & Max Planck Institute for Molecular Genetics
2001-2001	M.Sc. in Computer Science, Federal University Pernambuco, Brazil
1996-2000	B.Sc. in Computer Science, Federal University Pernambuco, Brazil

3. Academic degrees

01/2009	Assistant Professor for Computational Biology, Federal University of Pernambuco, Brazil
05/2008	PhD thesis (<i>summa cum laude</i>) in Bioinformatics
12/2001	M.Sc. in Computer Science

4. Scientific positions

since 11/2016	Associated Member of the Joint Research Center for Computational Biomedicine, RWTH Aachen
since 07/2012	Group Leader, Research Group Bioinformatics, IZKF Aachen & AICES Graduate School, RWTH Aachen
01/2009 – 05/2016	Assistant Professor, Center of Informatics, Federal University of Brazil
06/2008 – 12/2008	Postdoctoral fellow, Center of Informatics, Federal University of Brazil
04/2004 - 05/2008	Research Assistant, Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics

5. Other (function in editorial or advisory board, honours and awards)

since 2012	Member of the IZKF Board
since 2012	Editor for Frontiers in Plant Systems Biology
2007-2014	Bioinformatics Steering Committee, Brazilian Association of Computation
2013	Best Research Group, Day of the Medical Research, RWTH Aachen
2011	CNPq Research Fellowship
2004	DAAD/CNPq Ph.D. Scholarship

6. Most important publications

- [1] Gusmao, E. G., Allhoff, M., Zenke, M., **Costa, I. G. (2016)**: Analysis of computational footprinting methods for DNase sequencing experiments. *Nature Methods*, **13**, 303–309.
- [2] Allhoff, M., Sere, K., Freitas, J., Zenke, M., **Costa, I.G. (2016)**: Differential peak calling of ChIP-seq signals with replicates with THOR, *Nucleic Acids Res*, **44** (20); e153.
- [3] Kalwa, M., Hänzelmann, S., Otto, S., Kuo, C. C., Franzen, J., Joussem, S., Fernandez-Rebollo, E., Rath, B., Koch, C, Hofmann, A, Lee, S., Teschendorff, A.E., Denecke, B., Weinhold, E., **Costa, I. G.***, Wagner, W*. **(2016)**: The lncRNA HOTAIR impacts on mesenchymal stem cells via triple helix formation. *Nucleic Acids Res*, **44**, 10631-10643. shared corresponding authorship.
- [4] Lin, Q.* , Chauvistre, H.* , **Costa, I. G.***, Mitzka, S., Gusmao, E. G., Haenzelmann, S., Baying, B., Hennuy, B., Smeets, H., Hoffmann, K., Benes, V., Sere, K., Zenke, M. **(2015)**: Epigenetic and transcriptional architecture of dendritic cell development. *Nucleic Acids Res*, **43**, 9680-9693. shared first co-authorship.
- [5] Allhoff, M., Sere, K., Chauvistre, H., Lin, Q., Zenke, M., **Costa, I. G. (2014)**: Detecting differential peaks in ChIP-seq signals with ODIN. *Bioinformatics*, **30**, 3467-3475.
- [6] Gusmao, E. G., Dieterich, C., Zenke, M., **Costa, I. G. (2014)**: Detection of active transcription factor binding sites with the combination of DNase hypersensitivity and histone modifications. *Bioinformatics*, **30**, 3143-3151.
- [7] do Rego, T. G., Roider, H., de Carvalho, F. A., **Costa, I. G. (2012)**: Inferring epigenetic and transcriptional regulation during blood cell development with a mixture of sparse linear models. *Bioinformatics*, **28**, 2297-2303.
- [8] Redestig, H., **Costa, I.G. (2011)**: Detection and interpretation of metabolite-transcript co-responses using combined profiling data. *Bioinformatics*, **27**: i357-i365.
- [9] **Costa, I. G.**, Schoenhut, A., Hafemeister, C., Schliep, A. **(2009)**: Constrained mixture estimation for analysis and robust classification of clinical time series. *Bioinformatics*, **25**:i6-i14.
- [10] **Costa, I. G.**, Roepcke, S., Hafemeiste, C., Schliep, A. **(2008)**: Inferring differentiation pathways from gene expression. *Bioinformatics*, **24**: i156-i164.

Huber

1. General data

Huber, Michael, Univ.-Prof. Dr. rer. nat. *12.11.1967 (m)

Institute of Biochemistry and Molecular Immunology, University Hospital Aachen, RWTH Aachen University
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 88830
Fax: ++49 (0)241-80 82428
E-mail: mhuber@ukaachen.de



Director of the Institute, Professor (W2)

2. Scientific education

11/2002	Habilitation/ <i>Venia legendi</i> for Molecular Immunology, University of Freiburg
1993 - 1997	PhD at the Institute of Molecular Pathology, University of Tübingen
1992 - 1993	Diploma thesis at the Institute of Biochemistry, University of Bern
1988 - 1993	Studies in Chemistry/Biochemistry, Universities of Erlangen & Bern

3. Academic degrees

02/2009	W2 for Biochemistry and Molecular Immunology, UKA
12/2007	apl Professor assignment
11/2002	Habilitation in Molecular Immunology
03/1997	PhD thesis (<i>magna cum laude</i>) in Biochemistry
05/1993	Diploma in Biochemistry

4. Scientific positions

since 02/2013	Director of the Institute of Biochemistry and Molecular Immunology, UKA
02/2009 - 01/2013	Full Professor of Biochemistry and Molecular Immunology, Institute of Biochemistry and Molecular Biology, UKA
12/2007 – 01/2009	Associate Professor in Molecular Immunology, Institute for Biology III, University Freiburg and MPI for Immunobiology and Epigenetics, Freiburg
10/1999 - 11/2007	Assistant Professor in Molecular Immunology, Institute for Biology III, University Freiburg and MPI for Immunobiology and Epigenetics, Freiburg (Director Prof. Dr. M. Reth)
05/1997 - 07/1999	Postdoctoral fellow, Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada (Director Prof. Dr. G. Krystal)
07/1993 – 03/1997	Research assistant, Institute of Molecular Pathology, Medical Faculty, University of Tübingen (Director Prof. Dr. R. Kandolf)
1992 - 1993	Student assistant at the Institute of Biochemistry, University of Bern (Director Prof. Dr. B. Erni)

Huber

5. Other (function in editorial or advisory board, honours and awards)

since 2015	Editorial Board of "International Journal of Allergy Medications"
since 2014	Editorial Board of "Advances in Medicine"
2012	Innovation price of the Wiesheu-Foundation
2011-2014	Elected member of the Research Committee of the Medical Faculty
since 2011	Elected member of the Internal Advisory Board of the IZKF Aachen
since 2010	Scientific/Medical Advisory Board Leonardis Foundation, Germany
since 2010	Head of the Internal MD/PhD-program of the Medical Faculty
2004	Lecturer promotion of the Fonds of the German Chemical Industry
1994-1995	Kekulé-Dissertation Stipend of the Fonds of the German Chemical Industry

6. Most important publications

- [1] Zotz, J. S., Wölbing, F., Lassnig, C., Kauffmann, M., Schulte, U., Kolb, A., Whitelaw, B., Müller, M., Biedermann, T.*, **Huber, M.* (2016)**: CD13/amiopeptidase N is a negative regulator of mast cell activation. *FASEB J*, **30**, 2225-2235.
- [2] Kuhny, M., Hochdörfer, T., Ayata, C. K., Idzko, M., **Huber, M. (2014)**: CD39 is a negative regulator of P2X₇-mediated inflammatory cell death in mast cells. *Cell Commun Signal*, **12**, 40.
- [3] Zorn, C. N., Pardo, J., Martin, P., Kuhny, M., Simon, M. M., **Huber, M. (2013)**: Secretory lysosomes of mouse mast cells store and exocytose active caspase-3 in a strictly granzyme B-dependent manner. *Eur J Immunol*, **43**, 3209-3218.
- [4] Keck, S., Freudenberg, M., **Huber, M. (2010)**: Activation of murine macrophages via TLR2 and TLR4 is negatively regulated by a Lyn/PI3K module and promoted by SHIP1. *J Immunol*, **184**, 5809-5818.
- [5] Ali, S., **Huber, M.**, Kollwe, C., Bischoff, S. C., Falk, W., Martin, M. U. **(2007)**: The interleukin-1 receptor accessory protein is essential for interleukin-33 induced activation of T cells and mast cells. *Proc Natl Acad Sci USA*, **104**, 18660-18665.
- [6] **Huber, M.***, Kalis, C.*, Keck, S., Jiang, Z., Georgel, P., Du, X., Shamel, L., Sovath, S., Mudd, S., Beutler, B., Galanos, C., Freudenberg, M. **(2006)**: R-form LPS, the master key to the activation of TLR4/MD2 positive cells. *Eur J Immunol*, **36**, 701-711.
- [7] Jiang, Z., Georgel, P., Du, X., Shamel, L., Sovath, S., Mudd, S., **Huber, M.**, Kalis, C., Keck, S., Galanos, C., Freudenberg, M., Beutler, B. **(2005)**: CD14 is required for MyD88-independent LPS signaling. *Nat Immunol*, **6**, 565-570.
- [8] Gimborn, K., Lessmann, E., Kuppig, S., Krystal, G., **Huber, M. (2005)**: SHIP down-regulates Fc ϵ R1-induced degranulation at supra-optimal IgE or antigen levels. *J Immunol*, **174**, 507-516.
- [9] Kalesnikoff, J., **Huber, M.**, Damen, J. E., Bigg, C. M., Lam, V., Siraganian, R., Krystal, G. **(2001)**: Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. *Immunity*, **14**, 801-811.
- [10] **Huber, M.**, Helgason, C. D., Damen, J. E., Liu, L., Humphries, R. K., Krystal, G. **(1998)**: The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. *Proc Natl Acad Sci USA*, **95**, 11330-11335.

Koschmieder

1. General data

Koschmieder, Steffen, Univ.-Prof. Dr. med. *25.01.1971 (m)

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation
(Dept. of Medicine IV), RWTH Aachen University Hospital
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 36102
Fax: ++49 (0)241-80 802449
E-mail: skoschmieder@ukaachen.de



Professor (W2) of Translational Hematology and Oncology

2. Scientific education

07/2011	Board Certification in Hemostaseology
02/ 2009	Board Certification in Hematology and Medical Oncology
06/2007	Board Certification in Internal Medicine
1990-1997	Medical School at Bochum, Mainz, Dijon, Houston, Salt Lake City

3. Academic degrees

09/2011	Professor (W2) of Translational Hematology and Oncology at RWTH Aachen University, Faculty of Medicine
05/2008	Habilitation in Internal Medicine, Faculty of Medicine Westfälische Wilhelms-Universität Münster
07/1998	Doctoral thesis at the Department of Medicine

4. Scientific positions

since 09/2011	Professor (W2) of Translational Hematology and Oncology at the UKA; Attending Physician, Head of Clinical Hemostaseology & Head of Clinical Molecular Hematology Laboratory, Head of Basic Research; Department of Hematology, Oncology, Hemostaseology, and SCT
2004 - 08/2011	Resident Physician, then Attending Physician; Independent Research Group Leader, Lecturer; Head of Clinical Hematology & Immunophenotyping Laboratory; Department of Medicine (Hematology/ Oncology); Faculty of Medicine and University Hospital of Münster
02/2002 – 10/2004	Postdoctoral Research Fellowship (DFG grant), Harvard Institutes of Medicine, Boston, USA (Laboratory of Prof. Dr. Daniel G. Tenen)
05/1997 - 01/2002	Department of Internal Medicine (Hematology/ Oncology), University Hospital, J.-W. Goethe- University Frankfurt/ Main

5. Other (function in editorial or advisory board, honours and awards)

since 2016	Member of the European Hematology Association (EHA)
since 2015	Steering committee of the German Study Group – MPN (GSG-MPN)
since 2015	MPN WP9, European Leukemia Net
since 2014	Spokesperson of the IZKF-consortium of Myeloproliferative Neoplasms at the UKA (in conjunction with Prof. T. Brümmendorf)

Koschmieder

since 2013	Program committee for MPN of the DGHO
2013	Reinhard Osieka-Research Prize, Department of Medicine IV, UKA
since 2012	Secretary of the DGHO Hemostaseology Study Section, Steering group "Studienallianz Leukämie" (SAL)
2009	<i>Secundo loco</i> , Professorship (W2) Molecular Therapy Research, University Hospital Frankfurt/Main
2008	Research Junior Scientist Prize of the University of Münster
since 2006	Member of the "Deutsche Gesellschaft für Innere Medizin" (DGIM)
2005	PRO SCIENTIA-Research Award for basic research, awarded by the Buddecke-Stiftung, Münster
since 2004	American Society of Hematology (ASH)
since 1999	Membership DGHO

6. Most important publications

- [1] Han, L., Schubert, C., Köhler, J., Schemionek, M., Isfort, S., Brümmendorf, T. H., **Koschmieder, S.***, Chatain, N.* (2016): Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. *J Hematol Oncol*, **9**(1):45.
- [2] Halbach, S., Köhler, M., Uhl, F. M., Huber, J., Zeiser, R., Koschmieder, S., Aumann, K., Brummer, T. (2016): Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model. *Leukemia*, **30**, 1942-1945.
- [3] Brehme, M., Koschmieder, S., Montazeri, M., Copland, M., Oehler, V. G., Radich, J. P., Brümmendorf, T. H., Schuppert, A. (2016): Combined population dynamics and entropy modelling supports patient stratification in chronic myeloid leukemia. *Sci Rep* **6**, 24057.
- [4] Schemionek, M., Herrmann, O., Reher, M. M., Chatain, N., Schubert, C., Costa, I. G., Hänzelmann, S., Gusmao, E. G., Kintsler, S., Braunschweig, T., Hamilton, A., Helgason, G. V., Copland, M., Schwab, A., Müller-Tidow, C., Li, S., Holyoake, T. L., Brümmendorf, T. H., **Koschmieder, S.** (2016): Mtss1 is a critical epigenetically regulated tumor suppressor in CML. *Leukemia*, **30**, 823-832.
- [5] Giotopoulos, G., van der Weyden, L., Osaki, H., Rust, A. G., Gallipoli, P., Meduri, E., Horton, S. J., Chan, W. I., Foster, D., Prinjha, R. K., Pimanda, J. E., Tenen, D. G., Vassiliou, G. S., **Koschmieder, S.**, Adams, D. J., Huntly, B. J. (2015): A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. *J Exp Med*, **212**, 1551-1569.
- [6] Chatain, N., Perera, R. C., Rossetti, G., Rossa, J., Carloni, P., Schemionek, M., Haferlach, T., Brümmendorf, T. H., Schnittger, S., **Koschmieder, S.** (2015): Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine. *Leukemia*, **19**, 2434-2438.
- [7] Bolton-Gillespie, E., Schemionek, M., Klein, H. U., Flis, S., Hoser, G., Lange, T., Nieborowska-Skorska, M., Maier, J., Kerstiens, L., Koptyra, M., Müller, M. C., Modi, H., Stoklosa, T., Seferynska, I., Bhatia, R., Holyoake, T. L., **Koschmieder, S.**, Skorski, T. (2013): Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. *Blood*, **121**, 4175-4183.
- [8] Schemionek, M., Spieker, T., Kerstiens, L., Elling, C., Essers, M., Trumpp, A., Berdel, W. E., Müller-Tidow, C., **Koschmieder, S.** (2012): Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML. *Leukemia*, **26**, 1030-1037.
- [9] Chen, C. I.*, **Koschmieder, S.***, Kerstiens, L., Schemionek, M., Altvater, B., Pscherer, S., Gerss, J., Maecker, H. T., Berdel, W. E., Juergens, H., Lee, P. P., Rossig, C. (2012): NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. *Leukemia*, **26**, 465-474.
- [10] Hamilton, A.*, Helgason, G. V.*, Schemionek, M.*, Zhang, B., Myssina, S., Allan, E. K., Nicolini, F. E., Müller-Tidow, C., Bhatia, R., Brunton, V. G., **Koschmieder, S.***, Holyoake, T. L.*. (2012): Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. *Blood*, **119**, 1501-1510. * contributed equally.

Kramann

1. General data

Kramann, Rafael, Dr. med.

***19.11.1981 (m)**

Division of Nephrology and clinical Immunology
RWTH Aachen University Hospital
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 241-80 37750
Telefax: ++49 241-80 82446
E-mail: rkramann@ukaachen.de



Group Leader Division of Nephrology

2. Scientific education

2007	State board examination in Medicine, Germany
2002 - 2003	Research Technician Gruenthal Pharmaceuticals
2003 - 2006	Research Technician Institute of Pathology, RWTH Aachen University
2001 - 2007	Medical School RWTH Aachen University, Aachen Germany

3. Academic degrees

2008	Doctoral Thesis in Medicine, Department of Cardiology, RWTH Aachen University with Dr Rainer Hoffmann
------	---

4. Scientific positions

2015	Groupleader (www.kramannlab.com), Division of Nephrology and clinical Immunology, RWTH Aachen University, Aachen, Germany
2012 - 2015	Postdoctoral Research Fellow Brigham and Women's Hospital, Research Fellow Harvard Medical School, Boston, MA with Benjamin Humphreys, MD, PhD
2008 - 2011	Postdoctoral Research Fellow, Division of Nephrology and clinical Immunology, RWTH Aachen University
2005 - 2007	Graduate Student, Department of Cardiology, RWTH Aachen University

5. Other (function in editorial or advisory board, honours and awards)

2015	Awarded ERC Starting Grant (CureCKDHeart)
2015	Bernd Tersteegen Award of the Verband Deutsche Nierenzentren
2015	Carl Ludwig Award of the German Society of Nephrology (DGFN)
2014-2017	ERA-EDTA, ASN, ISN Abstract Reviewing Panel Board
2014	Kramann et al. Cell Stem Cell 2015 (epub 2014) selected as #1 Nephrology Story in 2014 by the Renal Fellow Network of the USA
2014	Fellow of the American Society of Nephrology (FASN) for Contribution to the Society and Excellence in Research
2014	Nils Alwall Award of the German Society of Nephrology (DGFN)

Kramann

- 2014 Stanley Shaldon Award, European Renal Association, European Dialysis and Transplant Association (ERA-EDTA)
- 2014 Career Development Award, American Society of Nephrology
- 2013 Winner of the inaugural Harvard Innovation Lab's Deans Health and Life Sciences Challenge "MatriTarg Laboratories: Targeting resident multipotent stem cells to develop new treatments for solid organ fibrotic disease" Boston, MA, USA
- 2013 Winner of the Harvard Stem Cell Institute Imaging Contest, Boston, MA
- 2011 German Society of Nephrology Award for Young Investigators
- 2011 Best Abstract Award, European Renal Association - European Dialysis and Transplant Association (ERA-EDTA), Prague, Czech Republic

6. Most important publications

- [1] Schneider, R. K., Mullally, A., Dugourd, A., Peisker, F., Hoogenboezem, R., van Strien, P. M., Bindels, E. M., Heckl, D., Büsche, G., Fleck, D., Müller-Newen, G., Wongboonsin, J., Ventura Ferreira, M., Puelles, V. G., Saez-Rodriguez, J., Ebert, B. L., Humphreys, B. D., **Kramann, R.**[#]. (2017): Gli1+ mesenchymal stromal cells are key drivers of bone marrow fibrosis and important cellular therapeutic targets. *Cell Stem Cell*, in press. [#]corresponding author
- [2] **Kramann, R.**[#] Goettsch, C., Wongboonsin, J., Iwata, H., Schneider, R. K., Kuppe, C., Kaesler, N., Chang-Panesso, M., Machado, F. G., Gratwohl, S., Madhurima, K., Hutcheson, J. D., Jain, S., Aikawa, E., Humphreys, B. D. (2016): Adventitial MSC-like cells are progenitors of vascular smooth muscle cells and drive vascular calcification in chronic kidney disease. *Cell Stem Cell*, **19**, 628-642. [#]corresponding author
- [3] **Kramann R.**[#] Wongboonsin J, Chang-Panesso M, Machado FG, Humphreys BD Gli1 pericyte loss induces capillary rarefaction and proximal tubular injury (2016). *J Am Soc Nephrol*, Epub ahead of print, [#]corresponding author
- [4] Schneider R.K., Schenone M., Ventura Ferreira M., **Kramann R.**, Joyce C.E., Hartigan C., Beier F., Brümmendorf T.H., Germing U., Platzbecker U., Buesche G., Knuechel R., Chen M.C., Waters C.S., Chen E., Chu L.P., Novina C., Lindsley R.C., Carr S.A., Ebert B.L. (2016): Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8/S100A9 - *Nature Med*, **22**, 288-297
- [5] **Kramann, R.**, Fleig, S. V., Schneider, R. K., Fabian, S. L., DiRocco, D. P., Maarouf, O., Wongboonsin, J., Ikeda, Y., Heckl, D., Chang, S. L., Rennke, H. G., Waikar, S. S., Humphreys, B. D. (2015): Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. *J Clin Invest*, **125**, 2935-2951.
- [6] **Kramann, R.**, Schneider, R. K., DiRocco, D. P., Machado, F., Fleig, S., Bondzie, P. A., Henderson, J. M., Ebert, B. L., Humphreys, B. D. (2015): Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. *Cell Stem Cell*, **16**, 51-66.
- [7] **Kramann, R.**, Erpenbeck, J., Schneider, R. K., Rohl, A. B., Hein, M., Brandenburg, V. M., van Diepen, M., Dekker, F., Marx, N., Floege, J., Becker, M., Schlieper, G. (2014): Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD. *J Am Soc Nephrol*, **25**, 2351-2365.
- [8] **Kramann, R.**, Tanaka, M., Humphreys, B. D. (2014): Fluorescence microangiography for quantitative assessment of peritubular capillary changes after AKI in mice. *J Am Soc Nephrol*, **25**, 1924-1931.
- [9] **Kramann, R.**, Kunter, U., Brandenburg, V. M., Leisten, I., Ehling, J., Klinkhammer, B. M., Knuchel, R., Floege, J., Schneider, R. K. (2013): Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease. *J Bone Miner Res*, **28**, 2523-2534.
- [10] **Kramann, R.**, Couson, S. K., Neuss, S., Kunter, U., Bovi, M., Bornemann, J., Knuchel, R., Jahnen-Dechent, W., Floege, J., Schneider, R. K. (2011): Exposure to uremic serum induces a procalcific phenotype in human mesenchymal stem cells. *Arterioscler Thromb Vasc Biol*, **31**, e45-54.

Lammers

1. General data

Lammers, Twan, Prof. Dr. Dr. *30.08.1979 (m)

Department of Nanomedicine and Theranostics
Institute for Experimental Molecular Imaging
University Hospital RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 241-80 36681
Telefax: ++49 241-80 3380116
E-mail: tlammers@ukaachen.de



Professor (W2), Head of Department of Nanomedicine and Theranostics

2. Scientific education

2002 MSc, Pharmacy and Pharmaceutical Sciences, Utrecht University
2001 Visiting Graduate Student, Pharmacology, Cornell University Medical College

3. Academic degrees

2009 PhD, Pharmaceutical Sciences, Utrecht University
2008 DSc, Radiation Oncology, Heidelberg University

4. Scientific positions

2014 Professor (W2), Nanomedicine and Theranostics, RWTH Aachen
2012 Asst. Professor (10%), Targeted Therapeutics, University of Twente
2009 Group Leader, Nanomedicine and Theranostics, RWTH Aachen

5. Other (function in editorial or advisory board, honours and awards)

2016 Editorial Board: ChemMedChem, Journal of Nanobiotechnology
2015 Controlled Release Society: CRS Young Investigator Award
2015 European Research Council: ERC Proof-of-Concept Grant
2015 Associate Editor (Europe): Journal of Controlled Release
2014 Council: European Society for Molecular Imaging
2013 Advisory Board: Cristal Therapeutics
2012 Chair: ESMI Study Group on Image-guided Drug Delivery
2012 Editorial Board: American Journal of Nuclear Medicine and Molecular Imaging, Clinical and Translational Imaging, Journal of Controlled Release, Theranostics

Lammers

2012	European Research Council: ERC Starting Grant
2011	Program Committee: EMIM, ESCDD, CLINAM, WMIC
2011	AstraZeneca: Image of the Year Award
2011	German Society for Biomedical Technology: Klee Prize (2. place)
2011	International Journal of Nanomedicine: Early Career Award
2011	Radiology: Editor's Recognition Award (with special distinction)

6. Most important publications

- [1] Ergen, C., Heymann, F., Al Rawashdeh, W., Gremse, F., Bartneck, M., Panzer, U., Pola, R., Pechar, M., Storm, G., Mohr, N., Barz, M., Zentel, R., Kiessling, F., Trautwein, C., **Lammers, T.***, Tacke, F.* (2017): Targeting distinct myeloid cell populations *in vivo* using polymers, liposomes and microbubbles. *Biomaterials*, **114**, 106-120.
- [2] Theek, B., Baues, M., Ojha, T., Möckel, D., Veettil, S., Steitz, J., Bloois, L., Storm, G., Kiessling, F., **Lammers, T.** (2016): Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. *J Control Release*, **231**, 77-85.
- [3] **Lammers, T.**, Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., Storm, G. Cancer nanomedicine: Is targeting our target? (2016): *Nat Rev Mater*, **1**, 16069.
- [4] Kunjachan, S., Ehling, J., Storm, G., Kiessling, F., **Lammers, T.** (2015): Non-invasive imaging of nanomedicines and nanotheranostics: Principles, progress and prospects. *Chem Rev*, **115**, 10907-10937.
- [5] **Lammers, T.**, Koczera, P., Fokong, S., Gremse, F., Vogt, M., Storm, G., Van Zandvoort, M., Kiessling, F. (2015): Theranostic USPIO-loaded microbubbles for mediating and monitoring blood-brain barrier permeation. *Adv Funct Mater*, **25**, 36-43.
- [6] Talelli, M., Barz, M., Rijcken, C., Kiessling, F., Hennink, W. E., **Lammers, T.** (2015): Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation. *Nano Today*, **10**, 93-117.
- [7] Ehling, J., Bartneck, M., Wie, X., Gremse, F., Fech, V., Eulberg, D., Luedde, T., Kiessling, F., **Lammers, T.***, Tacke, F.* (2014): CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. *Gut*, **63**, 1960-1971.
- [8] Kunjachan, S., Pola, R., Gremse, F., Theek, B., Ehling, J., Moeckel, D., Hermanns-Sachweh, B., Pechar, M., Ulbrich, K., Hennink, W. E., Storm, G., Lederle, W., Kiessling, F., **Lammers, T.** (2014): Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. *Nano Lett*, **14**, 972-981.
- [9] Mertens, M. E., Hermann, A., Buehren, A., Olde-Damink, L., Gremse, F., Ehling, J., Kiessling, F., **Lammers, T.** (2014): Iron oxide-labeled collagen scaffolds for non-invasive MR imaging in tissue engineering. *Adv Funct Mater*, **24**, 754-762.
- [10] Quan, L., Zhang, Y., Crielaard, B., Dusad, A., Rijcken, C., Metselaar, J., Kostkova, H., Etrych, T., Ulbrich, K., Kiessling, F., Mikuls, T., Hennink, W., Storm, G., **Lammers, T.***, Wang, D.* (2014): Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles and liposomes. *ACS Nano*, **8**, 458-468.

Lederle

1. General data

Lederle, Wiltrud, Dr. rer. nat.

***15.01.1972 (w)**

Institute for Experimental Molecular Imaging
University Hospital RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 36682
Fax: ++49 (0)241-80 3380116
E-mail: wlederle@ukaachen.de



Group leader

2. Scientific education

2003	PhD at the University of Hohenheim
1999 - 2003	PhD student at the German Cancer Research Centre (Heidelberg) and the University of Hohenheim
1992 – 1998	Studies in Biology, University of Freiburg
1991 – 1992	Studies in German literature and linguistics/History, University of Freiburg

3. Academic degrees

2003	PhD thesis (<i>magna cum laude</i>) in Biology
1998	Diploma in Biology

4. Scientific positions

since 2008	Group leader at the Institute for Experimental Molecular Imaging (Prof. Dr. F. Kiessling), RWTH Aachen University
2005 - 2008	Post-Doc at the German Cancer Research Centre, Heidelberg (Prof. Dr. M. Müller)
2003 - 2005	Post-Doc at the German Cancer Research Centre, Heidelberg (Prof. Dr. N. Fusenig)
1999 - 2003	Ph.D. student at the German Cancer Research Centre (Heidelberg) and the University of Hohenheim

5. Other (function in editorial or advisory board, honours and awards)

2015 - 2016	Category Subchair of the European Molecular Imaging Meeting (EMIM)
since 2015	Member of the AG START, Medical Faculty RWTH Aachen
since 2009	Reviewer for international scientific journals, e.g. Biomaterials, Journal of Controlled Release, Journal of Nuclear Medicine, International Journal of Cancer

6. Most important publications

- [1] Baetke, S. C., Rix, A., Tranquart, F., Schneider, R., Lammers, T., Kiessling, F., **Lederle, W. (2016)**: Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects. *Radiology*, **278**, 430-440.
- [2] Doleschel, D., Rix, A., Arns, S., Palmowski, K., Gremse, F., Merkle, R., Salopiata, F., Klingmüller, U., Jarsch, M., Kiessling, F., **Lederle, W. (2015)**: Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion. *Theranostics*, **5**, 905-918.
- [3] Torres-Rendon, J.G., Femmer, T., De Laporte, L., Tigges, T., Rahimi, K., Gremse, F., Zafarnia, S., **Lederle, W.**, Ifuku, S., Wessling, M., Hardy, J. G., Walther, A. **(2015)**: Bioactive gyroid scaffolds formed by sacrificial templating of nanocellulose and nanochitin hydrogels as instructive platforms for biomimetic tissue engineering. *Adv Mater*, **27**, 2989-2995.
- [4] Al Rawashdeh, W., Arns, S., Gremse, F., Ehling, J., Knüchel-Clarke, R., Kray, S., Spöler, F., Kiessling, F., **Lederle, W. (2014)**: Optical tomography of MMP activity allows a sensitive noninvasive characterization of the invasiveness and angiogenesis of SCC xenografts. *Neoplasia*, **16**, 235-246, 246.e1.
- [5] Depner, S.*, **Lederle, W.***, Gutschalk, C., Linde, N., Zajonz, A., Mueller, M. M. **(2014)**: Cell type specific interleukin-6 induced responses in tumor keratinocytes and stromal fibroblasts are essential for invasive growth. *Int J Cancer*, **135**, 551-562. *equal contribution.
- [6] Abou-Elkacem, L., Arns, S., Brix, G., Gremse, F., Zopf, D., Kiessling, F., **Lederle, W. (2013)**: Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. *Mol Cancer Ther*, **12**, 1322-1331.
- [7] Bzyl, J., Palmowski, M., Rix, A., Arns, S., Hyvelin, J. M., Pochon, S., Ehling, J., Schradling, S., Kiessling, F., **Lederle, W. (2013)**: The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55). *Eur Radiol*, **23**, 468-475.
- [8] Doleschel, D., Mundigl, O., Wessner, A., Gremse, F., Bachmann, J., Rodriguez, A., Klingmüller, U., Jarsch, M., Kiessling, F., **Lederle, W. (2012)**: Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts. *J Nucl Med*, **53**, 304-311.
- [9] **Lederle, W.**, Linde, N., Heusel, J., Bzyl, J., Woenne, E.C., Zwick, S., Skobe, M., Kiessling, F., Fusenig, N. E., Mueller, M.M. **(2010)**: Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. *Am J Pathol*, **176**, 981-994.
- [10] **Lederle, W.**, Hartenstein, B., Meides, A., Kunzelmann, H., Werb, Z., Angel, P., Mueller, M. M. **(2010)**: MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. *Carcinogenesis*, **31**, 1175-1184.

Liedtke

1. General data

Liedtke, Christian, Prof. Dr. rer. nat.

***23.05.1966 (m)**

Department of Internal Medicine III
University Hospital Aachen, RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80-89249
Fax: ++49 (0)241-80-82455
E-mail: cliedtke@ukaachen.de



Research Associate

2. Scientific education

- | | |
|-------------|--|
| 1993 - 1998 | PhD thesis at the Department of Genetics, Technical University of Braunschweig |
| 1986 - 1993 | Study of Biology, Technical University of Braunschweig, Diploma (Dipl.-Biol.) 17.02.1993 |

3. Academic degrees

- | | |
|---------|---|
| 07/2014 | Apl. Professor assignment by the Faculty of Medicine, RWTH Aachen |
| 04/2009 | Habilitation and <i>venia legendi</i> in Molecular and Experimental Medicine, RWTH Aachen, (Mentor: Prof. Dr. C. Trautwein) |
| 01/1998 | PhD (Dr. rer. nat.) in Genetics, Technical University Braunschweig (Mentor: Prof. Dr. H. Gutz) |
| 03/1993 | Diploma in Biochemistry, Genetics and Organic Chemistry, Technical University Braunschweig |

4. Scientific positions

- | | |
|-------------------|--|
| since 10/2005 | Scientific associate, Department of Medicine III, University Hospital Aachen (Director: Prof. Dr. C. Trautwein) |
| 2002 - 2005 | Research Assistant (C1) at the Medical School of Hannover, Dept. of Gastroenterology, Hepatology and Endocrinology |
| 1999 - 2002 | Postdoc at the Medical School of Hannover, Dept. of Gastroenterology, Hepatology and Endocrinology (Director: Prof. Dr. M. P. Manns) |
| 01/1998 - 12/1998 | Postdoc at Brandeis University, Waltham, Massachusetts (Dept. of Yeast Genetics, Head: Prof. Dr. James E. Haber) |
| 1993 - 1997 | PhD student, Technical University of Braunschweig, Dept. of Genetics (Director: Prof. Dr. H. Gutz) |

5. Other (function in editorial or advisory board, honours and awards)

- 2013 - present Member, Scientific Advisory Board, Transregional Collaborative Research Center 57 (SFB/TRR57)
- 2012 Invited reviewer in the scientific committee of the European Association for the Study of the Liver (EASL), category „Cell Cycle and Apoptosis“ (2012-2014)

6. Most important publications

- [1] Nevzorova, Y. A., Cubero, F. J., Hu, W., Hao, F., Haas, U., Ramadori, P., Gassler, N., Hoss, M., Strnad, P., Zimmermann, H. W., Tacke, F., Trautwein, C., **Liedtke, C. (2016)**: Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease. *J Hepatol*, **64**, 628-640.
- [2] Sonntag, R., Gassler, N., Bangen, J. M., Trautwein, C., **Liedtke, C. (2014)**: Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo. *Cell Death Dis*, **5**, e1030.
- [3] Hu, W., Nevzorova, Y. A., Haas, U., Moro, N., Sicinski, P., Geng, Y., Barbacid, M., Trautwein, C., **Liedtke, C. (2014)**: Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. *Hepatology*, **59**, 651-660.
- [4] Nevzorova, Y. A., Hu, W., Cubero, F. J., Haas, U., Freimuth, J., Tacke, F., Trautwein, C., **Liedtke, C. (2013)**: Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. *Biochim Biophys Acta*, **1832**, 1765-1775.
- [5] Freimuth, J., Bangen, J. M., Lambertz, D., Hu, W., Nevzorova, Y. A., Sonntag, R., Gassler, N., Riethmacher, D., Trautwein, C., **Liedtke, C. (2013)**: Loss of caspase-8 in hepatocytes accelerates the onset of liver regeneration in mice through premature nuclear factor kappa B activation. *Hepatology*, **58**, 1779-1789.
- [6] Nevzorova, Y. A., Bangen, J. M., Hu, W., Haas, U., Weiskirchen, R., Gassler, N., Huss, S., Tacke, F., Sicinski, P., Trautwein, C., **Liedtke, C. (2012)**: Cyclin E1 controls proliferation of hepatic stellate cells and is essential for liver fibrogenesis in mice. *Hepatology*, **56**, 1140-1149.
- [7] **Liedtke, C.**, Bangen, J. M., Freimuth, J., Beraza, N., Lambertz, D., Cubero, F. J., Hatting, M., Karlmark, K. R., Streetz, K. L., Krombach, G. A., Tacke, F., Gassler, N., Riethmacher, D., Trautwein, C. **(2011)**: Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. *Gastroenterology*, **141**, 2176-2187.
- [8] Bettermann, K., Vucur, M., Haybaeck, J., Koppe, C., Janssen, J., Heymann, F., Weber, A., Weiskirchen, R., **Liedtke, C.**, Gassler, N., Muller, M., de Vos, R., Wolf, M. J., Boege, Y., Seleznik, G. M., Zeller, N., Erny, D., Fuchs, T., Zoller, S., Cairo, S., Buendia, M. A., Prinz, M., Akira, S., Tacke, F., Heikenwalder, M., Trautwein, C., Luedde, T. **(2010)**: TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. *Cancer Cell*, **17**, 481-496.
- [9] Nevzorova, Y. A., Tschaharganeh, D., Gassler, N., Geng, Y., Weiskirchen, R., Sicinski, P., Trautwein, C., **Liedtke, C. (2009)**: Aberrant cell cycle progression and endoreplication in regenerating livers of mice that lack a single E-type cyclin. *Gastroenterology*, **137**, 691-703, 703 e691-696.
- [10] Beraza, N., Malato, Y., Sander, L. E., Al-Masaoudi, M., Freimuth, J., Riethmacher, D., Gores, G. J., Roskams, T., **Liedtke, C.**, Trautwein, C. **(2009)**: Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage. *J Exp Med*, **206**, 1727-1737.

Ohl

1. General data

Ohl, Kim, Dr. rer. nat.

***28.04.1982 (w)**

Department of Pediatrics, University Hospital Aachen, RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 37767
Fax: ++49 (0)241-80 82492
E-mail: kohl@ukaachen.de



Postdoc (Qualification for habilitation)

2. Scientific education

2008-2012	PhD at the Department of Pediatrics, University Hospital Aachen, RWTH Aachen
2008	Diploma thesis at the Institute of Biochemistry, Faculty of Medicine, RWTH Aachen
2005 - 2008	Studies in Biology, RWTH Aachen
2003 - 2005	Studies in Biology, University of Bonn

3. Academic degrees

06/2012	PhD thesis in Biology
09/2008	Diploma in Biology

4. Scientific positions

since 06/2012	Staff member (Post-Doc), Dept. Of Pediatrics, Medical Faculty, RWTH Aachen (Director Prof. Dr. N. Wagner)
10/2008-06/2012	Research assistant, Dept. Of Pediatrics, Medical Faculty, RWTH Aachen (Director Prof. Dr. N. Wagner)
01/2008-09/2008	Student assistant at the Institute of Biochemistry, Faculty of Medicine, RWTH Aachen (Director Prof. Dr. J. Bernhagen)
3/2007-5/2007	Student assistant at the Institute of Biology I, Faculty of Science, RWTH Aachen (Director Prof. Dr. F. Kreuzaler)

5. Other (function in editorial or advisory board, honours and awards)

2012	Abstract award of the European League against Rheumatism
2011	Science award of the German Society of Pediatric Rheumatology
2010	Science award of the German Society of Pediatric Rheumatology

6. Most important publications

- [1] **Ohl, K.***, A. Wiener*, R. Lippe, A. Schippers, C. Zorn, J. Roth, N. Wagner and K. Tenbrock (2016): CREM alpha enhances IL-21 production in T cells *in vivo* and *in vitro*. *Front Immunol*, **7**: 618.
* shared first authorship.

Ohl

- [2] Kuttkat, N., Mohs, A., **Ohl, K.**, Hooiveld, G., Longerich, T., Tenbrock, K., Cubero, F. J., Trautwein, C. (2016): Hepatic overexpression of cAMP-responsive element modulator alpha induces a regulatory T-cell response in a murine model of chronic liver disease. *Gut*, in press. doi: 10.1136/gutjnl-2015-311119. [Epub ahead of print].
- [3] Wiener, A., Schippers, A., Wagner, N., Tacke, F., Ostendorf, T., Honke, N., Tenbrock, K.*, **Ohl, K.***. (2016): CXCR5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking. *Clin Exp Immunol*, **185**, 22-32.
- [4] Verjans, E. *, **Ohl, K.***, Reiss, L.K., van Wijk, F., Toncheva, A.A., Wiener, A., Yu, Y., Rieg, A.D., Gaertner, V.D., Roth, J., Knol, E., Kabesch, M., Wagner, N., Uhlig, S., Martin, C., Tenbrock, K. (2015): The cAMP response element modulator (CREM) regulates TH2 mediated inflammation. *Oncotarget* **6**, 38538-38551. * shared first authorship.
- [5] **Ohl, K.**, Wiener, A., Schippers, A., Wagner, N., Tenbrock, K. (2015): Interleukin-2 treatment reverses effects of cAMP-responsive element modulator alpha-over-expressing T cells in autoimmune-prone mice. *Clin Exp Immunol*, **181**, 76-86.
- [6] **Ohl, K.**, Tenbrock, K. (2015): Regulatory T cells in systemic lupus erythematosus. *Eur J Immunol*, **45**, 344-355.
- [7] **Ohl, K.***, Eberhardt, C.*, Spink, C., Zahn, K., Wagner, N., Eggermann, T., Kemper, M.J., Querfeld, U., Hoppe, B., Harendza, S., Tenbrock, K. (2014): CTLA4 polymorphisms in minimal change nephrotic syndrome in children: a case-control study. *Am J Kidney Dis*, **63**, 1074-1075. * shared first authorship.
- [8] Honke, N., **Ohl, K.**, Wiener, A., Bierwagen, J., Peitz, J., Di Fiore, S., Fischer, R., Wagner, N., Wuller, S., Tenbrock, K. (2014): The p38-mediated rapid down-regulation of cell surface gp130 expression impairs interleukin-6 signaling in the synovial fluid of juvenile idiopathic arthritis patients. *Arthritis & Rheumatology* **66**, 470-478.
- [9] Verjans, E., **Ohl, K.**, Yu, Y., Lippe, R., Schippers, A., Wiener, A., Roth, J., Wagner, N., Uhlig, S., Tenbrock, K., Martin, C. (2013): Overexpression of CREMalpha in T cells aggravates lipopolysaccharide-induced acute lung injury. *J Immunol*, **191**, 1316-1323.
- [10] Lippe, R.*, **Ohl, K.***, Varga, G., Rauen, T., Crispin, J.C., Juang, Y.T., Kuerten, S., Tacke, F., Wolf, M., Roebrock, K., Vogl, T., Verjans, E., Honke, N., Ehrchen, J., Foell, D., Skryabin, B., Wagner, N., Tsokos, G. C., Roth, J., Tenbrock, K. (2012): CREMalpha overexpression decreases IL-2 production, induces a T(H)17 phenotype and accelerates autoimmunity. *J Mol Cell Biol* **4**, 121-123. * shared first authorship.

1. General data

Otto, Tobias, Dr. rer. nat.

***14.01.1980 (m)**

Department of Internal Medicine III
University Hospital RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 80662
Fax: ++49 (0)241-80 82455
E-mail: totto@ukaachen.de



Research Associate

2. Scientific education

2009 - 2016	Postdoctoral Research Fellow at the Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA (Supervisor: Prof. Dr. Piotr Sicinski)
2004 - 2008	PhD at the Institute of Molecular Biology and Tumor Research, Faculty of Medicine, Philipps-University of Marburg (Supervisor: Prof. Dr. Martin Eilers)
2004	Diploma thesis at the Paul Flechsig Institute for Brain Research, Faculty of Medicine, University of Leipzig (Supervisor: Prof. Dr. Thomas Arendt)
2001 – 2002	Studies in Biochemistry, University of Glasgow, Glasgow, UK
1999 - 2004	Studies in Biochemistry, University of Leipzig

3. Academic degrees

12/2008	PhD thesis (summa cum laude) in Biology
03/2004	Diploma in Biochemistry
07/2002	Bachelor of Science in Biochemistry

4. Scientific positions

Since 09/2016	Staff member (Research Associate), Department of Internal Medicine III, University Hospital RWTH Aachen
Since 02/2009	Staff member (Postdoctoral Research Fellow), Dana-Farber Cancer Institute (Department of Cancer Biology) and Harvard Medical School (Department of Genetics), Boston, MA, USA
2004 - 2008	Graduate student, Institute of Molecular Biology and Tumor Research, Faculty of Medicine, Philipps-University of Marburg
2003 – 2004	Undergraduate student, Paul Flechsig Institute for Brain Research, Faculty of Medicine, University of Leipzig

5. Other (function in editorial or advisory board, honours and awards)

2009	German Study Award (for best PhD thesis in natural and engineering sciences), Koerber Foundation
2009	MTTC (Molecular Targeted Therapy of Cancer Initiative) Award
2006	Prize for Outstanding Paper in Molecular and Cell Biology, Advances in Neuroblastoma Research Conference, Los Angeles, CA, USA
2003	Wolfgang-Natonek prize, University of Leipzig
2002	Amersham Biosciences prize, University of Glasgow, Glasgow, UK

6. Most important publications

- [1] **Otto, T.**, Candido, S. V., Pilarz, M. S., Sicinska, E., Bronson, R. T., Bowden, M., Lachowicz, I. A., Mulry, K., Jecrois, E. S., Sicinski, P. (2017): Cell cycle-targeting microRNAs promote differentiation by enforcing cell cycle exit. *Proc Natl Acad Sci U S A*, submitted.
- [2] Hydbring, P., Wang, Y., Fassl, A., Li, X., Matia, V., **Otto, T.**, Choi, Y. J., Sweeney, K. E., Suski, J. M., Yin, H., Bogorad, R. L., Goel, S., Yuzugullu, H., Kauffman, K. J., Yang, J., Jin, C., Li, Y., Floris, D., Swanson, R., Ng, K., Sicinska, E., Anders, L., Zhao, J. J., Polyak, K., Anderson, D. G., Li, C., Sicinski, P. (2017): Cell-cycle-targeting microRNAs as therapeutic tools against refractory cancers. *Cancer Cel*, in press.
- [3] **Otto, T.**, Sicinski, P. (2017): Cell cycle proteins as promising targets in cancer therapy. *Nat Rev Cancer*, **17**, 93-115.
- [4] **Otto, T.** (2015): MYCN and its posttranslational regulation in neuroblastoma. In: Christiansen H, Christiansen NM (eds): Progressive neuroblastoma: innovation and novel therapeutic strategies. *Pediatr Adolesc Med. Basel*, Karger, **20**, 47-58.
- [5] Li, N., Fassl, A., Chick, J., Inuzuka, H., Li, X., Mansour, M. R., Liu, L., Wang, H., King, B., Shaik, S., Gutierrez, A., Ordureau, A., **Otto, T.**, Kreslavsky, T., Baitsch, L., Bury, L., Meyer, C. A., Ke, N., Mulry, K. A., Kluk, M. J., Roy, M., Kim, S., Zhang, X., Geng, Y., Zagozdzon, A., Jenkinson, S., Gale, R. E., Linch, D. C., Zhao, J. J., Mullighan, C. G., Harper, J. W., Aster, J. C., Aifantis, I., von Boehmer, H., Gygi, S. P., Wei, W., Look, A. T., Sicinski, P. (2014): Cyclin C is a haploinsufficient tumour suppressor. *Nat Cell Biol.*, **16**, 1080-1091.
- [6] **Otto, T.**, Sicinski, P. (2013): The kinase-independent, second life of CDK6 in transcription. *Cancer Cell*, **24**, 141-143.
- [7] van Riggelen, J.* , Müller, J.* , **Otto, T.***, Beuger, V., Yetil, A., Choi, P. S., Kosan, C., Möröy, T., Felsher, D. W., Eilers, M. (2010): The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. *Genes Dev.*, **24**, 1281-1294. * these authors contributed equally
- [8] **Otto, T.**, Horn, S., Brockmann, M., Eilers, U., Schüttrumpf, L., Popov, N., Kenney, A. M., Schulte, J. H., Beijersbergen, R., Christiansen, H., Berwanger, B., Eilers, M. (2009): Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. *Cancer Cell*, **15**, 67-78.
- [9] Schulte, J. H.* , Horn, S.* , **Otto, T.**, Samans, B., Heukamp, L. C., Eilers, U. C., Krause, M., Astrahantseff, K., Klein-Hitpass, L., Buettner, R., Schramm, A., Christiansen, H., Eilers, M., Eggert, A., Berwanger, B. (2008): MYCN regulates oncogenic MicroRNAs in neuroblastoma. *Int J Cancer*, **122**, 699-704. * these authors contributed equally

Schemionek

1. General data

Schemionek, Mirle, Dr. rer. nat.

***03.03.1980 (f)**

Department of Hematology, Oncology, Hemostaseology and
Stem Cell Transplantation University Hospital Aachen, RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 37228
Fax: ++49 (0)241-80 82449
E-mail: mschemionek@ukaachen.de



Group Leader, Research Associate, Departmental Head of the Molecular Diagnostics

2. Scientific education

- 10/2005 – 05/2009 Ph.D. University of Muenster and University Hospital Muenster, Germany
- 06/2007 – 08/2008 Studies of Business economics for doctoral students Institute of Business Administration, University of Muenster, Germany
- 02 – 01/2005 Diploma thesis at the Institute of Molecular Biosciences, Massey University, New Zealand in cooperation with the University of Muenster, Germany
- 1999 - 2004 Studies in Biology, University of Muenster

3. Academic degrees

- 05/2009 Ph.D. (disputation, *summa cum laude*, dissertation, *summa cum laude/magna cum laude*, final grade, *magna cum laude*)
- 01/2005 Diploma in Biology (1.0)

4. Scientific positions

- since 04/2014 Research Associate, Group Leader, Head of the Molecular Diagnostics Laboratory, University Hospital RWTH Aachen, Germany
- 01/2012 – 03/2014 Postdoctoral Scientist, University Hospital RWTH Aachen, Germany and University of Massachusetts Medical School (Sept – Dec 2013), Worcester, USA
- 05/2009 – 12/2011 Postdoctoral Scientist, University Hospital Muenster, Germany
- 10/2005 – 04/2009 Research Scientist (PhD student), University Hospital Muenster, Germany
- 02/2005 – 08/2005 Research Scientist, Institute of Molecular Biosciences, Massey University, New Zealand

5. Other (function in editorial or advisory board, honours and awards)

- 2016 Invited speaker at the DGHO conference
- 2014 Scholarship received by the Novartis Foundation for Therapeutic Research
- 2013 Theodore von Kármán fellowship

6. Most important publications

- [1] Fahrenkamp, D., Herrmann, O., Koschmieder, S., Brummendorf, T. H., **Schemionek, M. (2017)**: Mtss1(CSC156) mutant mice fail to display efficient Mtss1 protein depletion. *Leukemia*, **31**, 1017-1019.
- [2] **Schemionek, M.**, Herrmann, O., Reher, M. M., Chatain, N., Schubert, C., Costa, I. G., Hanzelmann, S., Gusmao, E. G., Kintsler, S., Braunschweig, T., Hamilton, A., Helgason, G. V., Copland, M., Schwab, A., Muller-Tidow, C., Li, S., Holyoake, T. L., Brummendorf, T. H., Koschmieder, S. **(2016)**: Mtss1 is a critical epigenetically regulated tumor suppressor in CML. *Leukemia*, **30**, 823-832.
- [3] **Schemionek, M.**^{*}, Kharabi Masouleh, B.^{*}, Klaile, Y., Krug, U., Hebestreit, K., Schubert, C., Dugas, M., Buchner, T., Wormann, B., Hiddemann, W., Berdel, W. E., Brummendorf, T. H., Muller-Tidow, C., Koschmieder, S. **(2015)**: Identification of the adapter molecule MTSS1 as a potential oncogene-specific tumor suppressor in acute myeloid leukemia. *PLoS One*, **10**(5):e0125783. ^{*}co-first authors.
- [4] Kirschner, M. M.^{*}, **Schemionek, M.**^{*}, Schubert, C., Chatain, N., Sontag, S., Isfort, S., Ortiz-Bruchle, N., Schmitt, K., Kruger, L., Zerres, K., Zenke, M., Brummendorf, T. H., Koschmieder, S. **(2015)**: Dissecting genomic aberrations in myeloproliferative neoplasms by multiplex-PCR and next generation sequencing. *PLoS One*, **10**(4):e0123476. ^{*}co-first authors.
- [5] Bolton-Gillespie, E., **Schemionek, M.**, Klein, H. U., Flis, S., Hoser, G., Lange, T., Nieborowska-Skorska, M., Maier, J., Kerstiens, L., Koptyra, M., Muller, M. C., Modi, H., Stoklosa, T., Seferynska, I., Bhatia, R., Holyoake, T. L., Koschmieder, S., Skorski, T. **(2013)**: Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. *Blood*, **121**, 4175-4183.
- [6] **Schemionek, M.**, Spieker, T., Kerstiens, L., Elling, C., Essers, M., Trumpp, A., Berdel, W. E., Muller-Tidow, C., Koschmieder, S. **(2012)**: Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML. *Leukemia*, **26**, 1030-1037.
- [7] Hamilton, A.^{*}, Helgason, G. V.^{*}, **Schemionek, M.**^{*}, Zhang, B., Myssina, S., Allan, E. K., Nicolini, F. E., Muller-Tidow, C., Bhatia, R., Brunton, V. G., Koschmieder, S., Holyoake, T. L. **(2012)**: Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. *Blood*, **119**, 1501-1510. ^{*}co-first authors.
- [8] Chen, C. I., Koschmieder, S., Kerstiens, L., **Schemionek, M.**, Altvater, B., Pscherer, S., Gerss, J., Maecker, H. T., Berdel, W. E., Juergens, H., Lee, P. P., Rossig, C. **(2012)**: NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. *Leukemia*, **26**, 465-474.
- [9] Elling, C., Erben, P., Walz, C., Frickenhaus, M., **Schemionek, M.**, Stehling, M., Serve, H., Cross, N. C., Hochhaus, A., Hofmann, W. K., Berdel, W. E., Muller-Tidow, C., Reiter, A., Koschmieder, S. **(2011)**: Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. *Blood*, **117**, 2935-2943.
- [10] **Schemionek, M.**, Elling, C., Steidl, U., Baumer, N., Hamilton, A., Spieker, T., Gothert, J. R., Stehling, M., Wagers, A., Huettner, C. S., Tenen, D. G., Tickenbrock, L., Berdel, W. E., Serve, H., Holyoake, T. L., Muller-Tidow, C., Koschmieder, S. **(2010)**: BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. *Blood*, **115**, 3185-3195.

Tacke

1. General data

Tacke, Frank, Univ.-Prof. Dr. med., PhD *10.07.1973 (m)

Medizinische Klinik III
Uniklinik RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 35848
Fax: ++49 (0)241-80 82455
E-mail: ftacke@ukaachen.de



Associate Professor (W2) for Hepato-Gastroenterology
Executive Senior Physician (Leitender Oberarzt)

2. Scientific education

2004 - 2006	DFG postdoctoral fellow, Mount Sinai School of Medicine, New York
2002 - 2004	PhD Postgraduate Program "Molecular Medicine", MH Hannover
08/1998 - 08/1999	DAAD research fellowship, MD Anderson Cancer Center, Houston, TX
1994 - 2001	Medical School, Hannover, and Baylor College of Medicine, Houston

3. Academic degrees

since 10/2012	Associate Professor (W2) Hepato-Gastroenterology, RWTH Aachen
2016 - 2017	Advising Professor, Faculty of Medicine, University of Oslo, Norway
2014	Master of Health Business Administration, University Nürnberg
11/2014	Board certification <i>Infectious Diseases</i>
07/2012	Board certification <i>Intensive Care Medicine</i>
01/2011	Board certification <i>Gastroenterology</i>
10/2008	Board certification <i>Internal Medicine</i>
12/2007	Habilitation and <i>venia legendi</i> , Internal Medicine, RWTH Aachen
11/2004	PhD, Dept. of Gastroenterology/Hepatology, MH Hannover
08/2002	MD (Dr. med.), Dept. of Hematology/Oncology, MH Hannover

4. Scientific positions

since 04/2013	Executive Senior Physician (geschäftsführender/leitender Oberarzt)
since 11/2008	Consultant (Oberarzt), Dept of Medicine III, University Hospital Aachen
2007 - 2014	Emmy Noether Group „Monocyte subset biology“ (DFG Ta434/2-1)
since 07/2006	Research Group Leader and Clinical Fellow, RWTH Aachen
04/2004 - 06/2006	Postdoctoral Fellow at Mount Sinai School of Medicine, NY, USA
07/2001 - 04/2004	Gastroenterology, Hepatology & Endocrinology, MH Hannover

5. Other (function in editorial or advisory board, honours and awards)

2014 – 2019	Governing Board European Association for the Study of the Liver
2009 –	Associate Editor: J Hepatol (Web Editor), Liver Int, BMC Gastroenterol, Hepatitis Monthly, Langenbeck's Archives of Surgery
2013 – 2017	DGVS (vice) spokesperson AG „Intensive Care Medicine“
2011 – 2014	DGVS abstract selection committee „liver & bile“
since 2011	UEGW abstract selection committee „liver & bile“
2011	Rising Star Award (ASNEMGE / UEGF)
2008 - 2014	spokesperson “inflammation and consequences“, IZKF RWTH Aachen
2008	Friedrich-Wilhelm-Award, RWTH Aachen
2005	YI Award European Macrophage and Dendritic Cell Society

6. Most important publications

- [1] Krenkel, O., **Tacke, F. (2017)**: Liver macrophages in tissue homeostasis and disease. *Nat Rev Immunol*, in press. doi: 10.1038/nri.2017.11. [Epub ahead of print].
- [2] Mossanen, J.C., Krenkel, O., Ergen, C., Govaere, O., Liepelt A., Puengel, T., Heymann, F., Kalthoff, S., Lefebvre, E., Eulberg, D., Luedde, T., Marx, G., Strassburg, C.P., Roskams T., Trautwein, C., **Tacke, F. (2016)**: Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury. *Hepatology*, **64**, 1667-1682.
- [3] Bartneck, M., Fech, V., Ehling, J., Govaere, O., Warzecha, K. T., Hittatiya, K., Vucur, M., Gautheron, J., Luedde, T., Trautwein, C., Lammers, T., Roskams, T., Jahnen-Dechent, W., **Tacke, F. (2016)**: Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease. *Hepatology*, **63**, 1310-1324.
- [4] Heymann, F., **Tacke, F. (2016)**: Immunology in the liver - from homeostasis to disease. *Nat Rev Gastroenterol Hepatol*, **13**, 88-110.
- [5] Heymann, F., Peusquens, J., Ludwig-Portugall, I., Kohlhepp, M., Ergen, C., Niemietz, P., Martin, C., van Rooijen, N., Ochando, J. C., Randolph, G. J., Luedde, T., Ginhoux, F., Kurts, C., Trautwein, C., **Tacke, F. (2015)**: Liver inflammation abrogates immunological tolerance induced by Kupffer cells. *Hepatology*, **62**, 279-291.
- [6] Ehling, J., Bartneck, M., Wei, X., Gremse, F., Fech, V., Mockel, D., Baeck, C., Hittatiya, K., Eulberg, D., Luedde, T., Kiessling, F., Trautwein, C., Lammers, T., **Tacke, F. (2014)**: CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. *Gut*, **63**, 1960-1971.
- [7] Baeck, C., Wei, X., Bartneck, M., Fech, V., Heymann, F., Gassler, N., Hittatiya, K., Eulberg, D., Luedde, T., Trautwein, C., **Tacke, F. (2014)**: Pharmacological inhibition of the chemokine CCL2 accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. *Hepatology*, **59**, 1060-1072.
- [8] Marra, F., **Tacke, F. (2014)**: Roles for chemokines in liver disease. *Gastroenterology*, **147**, 577-594 e571.
- [9] **Tacke, F.**, Alvarez, D., Kaplan, T. J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., Lira, S. A., Habenicht, A. J., Randolph, G. J. **(2007)**: Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. *J Clin Invest* **117**, 185-194.
- [10] **Tacke, F.**, Ginhoux, F., Jakubzick, C., van Rooijen, N., Merad, M., Randolph, G. J. **(2006)**: Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. *J Exp Med*, **203**, 583-597.

Tenbrock

1. General data

Tenbrock, Klaus, Prof. Dr. med. *31.07.1968 (m)

Dept of Pediatrics
University Hospital Aachen, RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 35486
Fax: ++49 (0)241-80 82599
E-mail: ktenbrock@ukaachen.de



Physician (Oberarzt)

2. Scientific education

1992 - 1995	Scholarship „Studienstiftung des Deutschen Volkes“ (Top 1% students in Germany)
1988 - 1995	Studies of Medicine, RWTH Aachen

3. Academic degrees

03/2015	Apl. Professor assignment
11/2013	board certified pediatric allergologist
04/2008	board certified pediatric pneumologist
05/2007	Venia Legendi (Habilitation) for Pediatrics, University of Muenster
06/2006	Board certified pediatric Rheumatologist
05/2005	Board certified Pediatrician
10/1996	MD thesis
05/1995	Staatsexamen (Medicine)

4. Scientific positions

since 2007	Consultant Pediatric Pneumologist, Allergologist, Rheumatologist, Immunologist, Dept of Pediatrics, RWTH Aachen
2003 - 2007	Research group leader, Interdisciplinary Center for clinical research (IZKF) / University of Münster, Germany
2001 - 2003	Research Fellow at the Walter Reed Army Institute of Research, Washington (DFG-supported)
1995 - 2001	training in general pediatrics, department of pediatrics, University of Cologne

5. Other (function in editorial or advisory board, honours and awards)

actually	Reviewer for the DFG, Belgian national research organization (FWO), Dutch arthritis foundation, various other international universities
----------	--

Tenbrock

actually	Reviewer of scientific journals such as PNAS, Trends in Immunology, Arthritis and Rheumatology, PLoS ONE, Journal of Immunology, and others
actually	Member of the European Pediatric Rheumatology Society (PRES), of the German Society of Immunology (DGFI), of the German Pediatric Pneumology Society (GPP). Chairman of the Clinical Studies group within the German Pediatric Rheumatology Society (GKJR)
2002	Henry Christian Award of the American Federation for Medical Research

6. Most important publications

- [1] Yoshida, N., Comte, D., Mizui, M., Otomo, K., Rosetti, F., Mayadas, T., Crispín, J., Bradley, S., Koga, T., Kono, M., Karampetsou, M., Kyttaris, V., **Tenbrock, K.**, Tsokos, G. (2016): *Nat Commun*, **7**:12993.
- [2] Ohl, K., Wiener, A., Lippe, R., Zorn, C., Roth, J., Wagner, N., Schippers, A., **Tenbrock, K.** (2016): CREM alpha regulates IL-21 expression by direct and indirect transcriptional mechanisms. *Front Immunol*, **7**:618.
- [3] Kuttkat, N., Ohl, K., Mohs, A., Hooiveld, G., Longerich, T., **Tenbrock, K.**, Trautwein, C., Cubero, F.J. (2016): Hepatic overexpression of cAMP-responsive element modulator alpha (CREM α) induces a regulatory T-cell response in a murine model of chronic liver disease. *Gut*, in press. doi: 10.1136/gutjnl-2015-311119. [Epub ahead of print]
- [4] Verjans, E., Ohl, K., Reiss, L. K., van Wijk, F., Toncheva, A. A., Wiener, A., Yu, Y., Rieg, A. D., Gaertner, V. D., Roth, J., Knol, E., Kabesch, M., Wagner, N., Uhlig, S., Martin, C., **Tenbrock, K.** (2015): The cAMP response element modulator (CREM) regulates TH2 mediated inflammation. *Oncotarget*, **6**, 38538-38551.
- [5] Ohl, K., Wiener, A., Schippers, A., Wagner, N., **Tenbrock, K.** (2015): Interleukin-2 treatment reverses effects of cAMP-responsive element modulator α -over-expressing T cells in autoimmune-prone mice. *Clin Exp Immunol*, **181**, 76-86.
- [6] Hammerich, L., Warzecha, K. T., Stefkova, M., Bartneck, M., Ohl, K., Gassler, N., Luedde, T., Trautwein, C., **Tenbrock, K.**, Tacke, F. (2015): CREM α overexpression impairs function of hepatic myeloid derived suppressor cells and aggravates immune-mediated hepatitis in mice. *Hepatology*, **61**, 990-1002.
- [7] Liu, Y., Jesus, A. A., Marrero, B., Yang, D., Ramsey, S. E., Montealegre Sanchez, G.A., **Tenbrock, K.**, Wittkowski, H., Jones, O. Y., Kuehn, H. S., Lee, C. C., DiMattia, M. A., Cowen, E. W., Gonzalez, B., Palmer, I., DiGiovanna, J. J., Biancotto, A., Kim, H., Tsai, W. L., Trier, A. M., Huang, Y., Stone, D. L., Hill, S., Kim, H. J., St Hilaire, C., Gurprasad, S., Plass, N., Chapelle, D., Horkayne-Szakaly, I., Foell, D., Barysenka, A., Candotti, F., Holland, S. M., Hughes, J. D., Mehmet, H., Issekutz, A. C., Raffeld, M., McElwee, J., Fontana, J. R., Minniti, C. P., Moir, S., Kastner, D. L., Gadina, M., Steven, A. C., Wingfield, P. T., Brooks, S. R., Rosenzweig, S. D., Fleisher, T. A., Deng, Z., Boehm, M., Paller, A. S., Goldbach-Mansky, R. (2014): Activated STING in a vascular and pulmonary syndrome. *N Engl J Med*, **371**, 507-518.
- [8] Honke, N., Ohl, K., Wiener, A., Bierwagen, J., Peitz, J., Di Fiore, S., Fischer, R., Wagner, N., Wüller, S., **Tenbrock, K.** (2014): The p38-mediated rapid down-regulation of cell surface gp130 expression impairs interleukin-6 signaling in the synovial fluid of juvenile idiopathic arthritis patients. *Arthritis Rheumatol*, **66**, 470-478.
- [9] Lippe, R., Ohl, K., Varga, G., Rauen, T., Crispin, J. C., Juang, Y. T., Kuerten, S., Tacke, F., Wolf, M., Roebrock, K., Vogl, T., Verjans, E., Honke, N., Ehrchen, J., Foell, D., Skryabin, B., Wagner, N., Tsokos, G. C., Roth, J., **Tenbrock, K.** (2012): CREM α overexpression decreases IL-2 production, induces a TH17 phenotype and accelerates autoimmunity. *J Mol Cell Biol*, **4**, 121-123.
- [10] Vogl, T., **Tenbrock, K.**, Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A., Nacken, W., Foell, D., van der Poll, T., Sorg, C., Roth, J. (2007): Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. *Nat Med*, **13**, 1042-1049.

1. General data

Trautwein, Christian, Univ.-Prof. Dr. med. *04.06.1960 (m)

Medizinische Klinik III
Uniklinik RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen



Phone: ++49 (0)241-80 80866
Fax: ++49 (0)241-80 82455
E-mail: ctrautwein@ukaachen.de

Head of Department, Professor (W3)

2. Scientific education

01/2011	State board examination in Intensive Care Medicine
10/1996	State board examination in Gastroenterology
08/1995	State board examination in Internal Medicine
1981 - 1987	Medical School, Johannes-Gutenberg University, Mainz and Eberhard-Karl University, Tübingen

3. Academic degrees

10/1996	Habilitation and <i>venia legendi</i> for Internal Medicine, MHH Hannover Medical School, Prof. M. P. Manns
11/1987	Doctoral Thesis in Medicine, Johannes-Gutenberg University, Mainz, Prof. M. P. Manns

4. Scientific positions

Since 09/2005	Director, Department of Internal Medicine III, University Hospital, RWTH Aachen
01/2003	Associate Professor (C3-Professor), Medical School Hannover
10/2000 - 08/2005	Senior Consultant (Leitender Oberarzt), Vice-Director, Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover (Director: Prof. Dr. M.P. Manns)
04/1993 - 03/1995	Internship, Department of Gastroenterology and Hepatology, Medical School, Hannover (Director: Prof. Dr. M.P. Manns)
04/1991 - 03/1993	Postdoctoral fellow, Department of Pharmacology, Signal Transduction and Gene Transcription Laboratory (Head: Prof. Dr. M. Karin), University of California, San Diego, USA.
07/1990 - 09/1990	Fellowship, Liver and Transplant Unit, Queen Elizabeth-Hospital, Birmingham, U.K. (Head: Prof. Dr. E. Elias and Prof. Dr. J. Neuberger)
04/1988 - 03/1991	Internship, Department of Internal Medicine I, Johannes-Gutenberg-University, Mainz (Director: Prof. Dr. Dr. K.-H. Meyer zum Büschenfelde)
07/1987 - 03/1988	Internship, Internal Medicine, Kreiskrankenhaus Nürtingen (Director: Dr. J. Breuning)

5. Other (function in editorial or advisory board, honours and awards)

since 2013	Member of the executive board of the DGVS (Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselerkrankungen)
------------	---

since 2012	Member of the executive board of the Ackermann Foundation
since 2011	Member of the strategic Council of the RWTH Aachen
since 2009	Spokesman of the Faculty Focus "Inflammation and consequences"
since 2014	Member of the board of the new excellence Initiative of the RWTH Associate Editor: Journal of Hepatology
2011 - 2015	Editor: BMC Gastroenterology
2006 - 2011	Associate Editor: Hepatology
2006 - 2010	Associate Editor: Liver transplantation
2006 - 2009	Member of the International Board of the American Association for the study of the liver (AASLD)
2006 - 2009	Associate Editor: Journal of Hepatology
2003 - 2006	Scientific Committee of the European Association for the study of the liver (EASL)
02/2003 - 08/2005	Member of the Steering Committee Center of Internal Medicine; Medical, School Hannover

6. Most important publications

- [1] Cubero, F. J., Zoubek, M. E., Hu, W., Peng, J., Zhao, G., Nevzorova, Y. A., Al Masaoudi, M., Bechmann, L. P., Boekschoten, M. V., Muller, M., Preisinger, C., Gassler, N., Canbay, A. E., Luedde, T., Davis, R. J., Liedtke, C., **Trautwein, C. (2016)**: Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury. *Gastroenterology*, **150**, 968-981.
- [2] Schneider, K. M., Bieghs, V., Heymann, F., Hu, W., Drey Mueller, D., Liao, L., Frissen, M., Ludwig, A., Gassler, N., Pabst, O., Latz, E., Sellge, G., Penders, J., Tacke, F., **Trautwein, C. (2015)**: CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: Limiting steatohepatitis by maintaining intestinal homeostasis. *Hepatology*, **62**, 1405-1416.
- [3] Kroy, D. C., Cubero, F. J., Zhao, G., Nevzorova, Y. A., Hatting, M., Al Masaoudi, M., Verdier, J., Peng, J., Schaefer, F. M., Hermanns, N., Boekschoten, M. V., Grouls, C., Gassler, N., Kiessling, F., Muller, M., Davis, R. J., Liedtke, C., **Trautwein, C. (2015)**: Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury. *J Hepatol*, **62**, 140-149.
- [4] D. C., Schumacher, F., Ramadori, P., Hatting, M., Bergheim, I., Gassler, N., Boekschoten, M. V., Muller, M., Streetz, K. L., **Trautwein, C. (2014)**: Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. *J Hepatol*, **61**, 883-890.
- [5] Zhao, G., Hatting, M., Nevzorova, Y. A., Peng, J., Hu, W., Boekschoten, M. V., Roskams, T., Muller, M., Gassler, N., Liedtke, C., Davis, R. J., Cubero, F. J., **Trautwein, C. (2014)**: Jnk1 in murine hepatic stellate cells is a crucial mediator of liver fibrogenesis. *Gut*, **63**, 1159-1172.
- [6] Hatting, M., Zhao, G., Schumacher, F., Sellge, G., Al Masaoudi, M., Gabetaler, N., Boekschoten, M., Muller, M., Liedtke, C., Cubero, F. J., **Trautwein, C. (2013)**: Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents. *Hepatology*, **57**, 2189-2201.
- [7] Y Malato, Y., Ehedego, H., Al-Masaoudi, M., Cubero, F. J., Bornemann, J., Gassler, N., Liedtke, C., Beraza, N., **Trautwein, C. (2012)**: NF-kappaB essential modifier is required for hepatocyte proliferation and the oval cell reaction after partial hepatectomy in mice. *Gastroenterology*, **143**, 1597-1608 e1511.
- [8] Liedtke, C., Bangen, J. M., Freimuth, J., Beraza, N., Lambertz, D., Cubero, F. J., Hatting, M., Karlmark, K. R., Streetz, K. L., Krombach, G. A., Tacke, F., Gassler, N., Riethmacher, D., **Trautwein, C. (2011)**: Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. *Gastroenterology*, **141**, 2176-2187.
- [9] Sander, L. E., Sackett, S. D., Dierssen, U., Beraza, N., Linke, R. P., Muller, M., Blander, J. M., Tacke, F., **Trautwein, C. (2010)**: Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. *J Exp Med*, **207**, 1453-1464.
- [10] Beraza, N., Malato, Y., Sander, L. E., Al-Masaoudi, M., Freimuth, J., Riethmacher, D., Gores, G. J., Roskams, T., Liedtke, C., **Trautwein, C. (2009)**: Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage. *J Exp Med*, **206**, 1727-1737.

Vervoorts

1. General data

Vervoorts, Jörg, Dr. rer. nat.

***16.01.1970 (m)**

Institute of Biochemistry and Molecular Biology
University Hospital Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 88851
Fax: ++49 (0)241-80 82427
E-mail: jvervoorts-weber@ukaachen.de



Akademischer Oberrat (A14)

2. Scientific education

1998 - 2001 PhD at the Institute of Molecular Biology, Medical School Hanover
1997 Diploma thesis at the Institute of Molecular Biology, Medical School Hanover
1992 - 1997 Studies in Biochemistry, University of Hannover

3. Academic degrees

12/2001 PhD thesis in Biochemistry
12/1997 Diploma in Biochemistry

4. Scientific positions

since 03/2015 Akademischer Oberrat, Institute of Biochemistry and Molecular Biology, UKA
01/2010 – 02/2015 Akademischer Rat, Institute of Biochemistry and Molecular Biology, UKA
09/2005 -12/2009 Staff member, Institute of Biochemistry and Molecular Biology, RWTH University Hospital Aachen
09/2001 - 07/2005 Post-Doc, Clinic for Gastroenterology and Hepatology, Medical School Hannover (Group of Prof. Dr. Nisar Malek)
01/1998 - 08/2001 PhD-student, Institute of Molecular Biology, Medical School Hannover (Group of Prof. Dr. Bernhard Lüscher)

6. Most important publications

- [1] Li, J.*, **Vervoorts, J.***, Carloni, P., Rossetti, G., Lüscher, B. (2017): Structural prediction of the interaction of the tumor suppressor p27KIP1 with cyclin A/CDK2 identifies a novel catalytically relevant determinant. *BMC Bioinformatics*, **18**(15), 1-9. * equal contribution.
- [2] Linzen, U., Lilischkis, R., Pandithage, R., Schilling, B., Ullius, A., Lüscher-Firzlaff, J., Kremmer, E., Lüscher, B.*, **Vervoorts, J.*** (2015): ING5 is phosphorylated by CDK2 and controls cell proliferation independently of p53. *PLoS One*, **10**(4), e0123736.
- [3] Ullius, A., Lüscher-Firzlaff, J., Costa, I. G., Walsemann, G., Forst, A. H., Gusmao, E. G., Kapelle, K., Kleine, H., Kremmer, E., **Vervoorts, J.***, Lüscher, B.* (2014): The interaction of MYC with the

Vervoorts

trithorax protein ASH2L promotes gene transcription by regulating H3K27 modification. *Nucleic Acids Res*, **42**, 6901-6920.

- [4] Vollrath, J. T., Sechi, A., Dreser, A., Katona, I., Wiemuth, D., **Vervoorts, J.**, Dohmen, M., Chandrasekar, A., Prause, J., Brauers, E., Jesse, C. M., Weis, J., Goswami, A. **(2014)**: Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances. *Cell Death Dis*, **12**(5), e1290.
- [5] Lüscher, B. and J. Vervoorts **(2012)**: Regulation of gene transcription by the oncoprotein MYC. *Gene*, **494**, 145-160.
- [6] Kossatz, U. *, **Vervoorts, J.***, Nickeleit, I. *, Sundberg, H.M., Arthur, J.S., Manns, M. P., Malek, N. P. **(2006)**: C-terminal phosphorylation controls the stability and function of p27kip1. *EMBO J*, **25**, 5159-5170. * equal contribution.
- [7] **Vervoorts, J.**, Lüscher-Firzlaff, J. M., Rottmann, S., Lilischkis, R., Walsemann, G., Dohmann, K., Austen, M., Lüscher, B. **(2003)**: Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. *EMBO Rep*, **4**, 484-490.
- [8] **Vervoorts, J.** and Lüscher, B. **(1999)**: DNA binding of Myc/Max/Mad network complexes to oligonucleotides containing two E box elements: c-Myc/Max heterodimers do not bind DNA cooperatively. *Biol Chem*, **380**, 1121-1126.

Vucur

1. General data

Vucur, Mihael, Dr. rer. nat.

***18.09.1982 (m)**

Department of Medicine III, Division of Gastroenterology, Hepatology and Hepatobiliary Oncology
University Hospital Aachen, RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 88189
Fax: ++49 (0)241-80 82455
E-mail: mvucur@ukaachen.de



Postdoc (Qualification for habilitation)

2. Scientific education

since 07/2013	Postdoc at the Department of Medicine III, Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, University Hospital Aachen, Germany
2008 - 2013	PhD thesis at the Department of Medicine III, University Hospital Aachen, Germany
2007 - 2008	Diploma thesis at the Center for Biotechnology (CeBiTec), University of Bielefeld, Germany
2002 - 2008	Studies in Biology, University of Bielefeld, Germany

3. Academic degrees

07/2013	PhD (<i>magna cum laude</i>) in Biology, Supervisor: Prof. Dr. T. Lüdde
03/2008	Diploma in Biology, Supervisor: Prof. Dr. K. Niehaus

4. Scientific positions

since 07/2013	Postdoctoral Fellow, Department of Medicine III, Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, University Hospital Aachen, (Head: Prof. Dr. T. Lüdde)
2008 - 2013	Research assistant, Department of Medicine III, University Hospital Aachen (Head: Prof. Dr. T. Lüdde)
2007 - 2008	Student assistant, Center for Biotechnology (CeBiTec), University of Bielefeld (Head: Prof. Dr. K. Niehaus)

5. Other (function in editorial or advisory board, honours and awards)

2014	Best paper award from the Medical Faculty of the RWTH Aachen
2012	Novartis graduate award for therapeutic research

6. Most important publications

- [1] Schneider, A. T., Gautheron, J., Feoktistova, M., Roderburg, C., Loosen, S. H., Roy, S., Benz, F., Schemmer, P., Büchler, M. W., Nachbur, U., Neumann, U. P., Tolba, R., Luedde, M., Zucman-Rossi, J., Panayotova-Dimitrova, D., Leverkus, M., Preisinger, C., Tacke, F., Trautwein, C., Longerich, T., **Vucur, M.**[#], Luedde, T.[#] (2017): RIPK1 suppresses a TRAF2-dependent pathway to liver cancer. *Cancer Cell*, **31**, 94-109. [featured article]. [#] equal contribution.
- [2] Gautheron, J.[#], **Vucur, M.**[#], Schneider, A. T., Severi, I., Roderburg, C., Roy, S., Bartneck, M., Schrammen, P., Diaz, M. B., Ehling, J., Gremse, F., Heymann, F., Koppe, C., Lammers, T., Kiessling, F., Van Best, N., Pabst, O., Courtois, G., Linkermann, A., Krautwald, S., Neumann, U. P., Tacke, F., Trautwein, C., Green, D. R., Longerich, T., Frey, N., Luedde, M., Bluher, M., Herzig, S., Heikenwalder, M., Luedde, T. (2016): The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance. *Nat Commun*, **7**, 11869. [#] equal contribution.
- [3] Schneider A.T., Gautheron J., Tacke F., **Vucur M.**[#], Luedde T.[#] (2016): Receptor Interacting Protein Kinase-1 (RIPK1) in hepatocytes does not mediate murine acetaminophen toxicity. *Hepatology*, **64**, 306-308. [#] equal contribution.
- [4] Koppe, C., Verheugd, P., Gautheron, J., Reisinger, F., Kreggenwinkel, K., Roderburg, C., Quagliata, L., Terracciano, L., Gassler, N., Tolba, R., Boege, Y., Weber, A., Karin, M., Luedde, M., Neumann, U. P., Weiskirchen, R., Tacke, F., **Vucur, M.**, Trautwein, C., Lüscher, B., Preisinger, C., Heikenwalder, M., Luedde, T. (2016): IKK α/β control hepatocarcinogenesis and biliary homeostasis in mice by phosphorylating the cell-death mediator RIPK1. *Hepatology*, **64**, 1217-1231.
- [5] Bartneck, M., Fech, V., Ehling, J., Govaere, O., Theresa Warzecha, K., Hittatiya, K., **Vucur, M.**, Gautheron, J., Luedde, T., Trautwein, C., Lammers, T., Roskams, T., Jahnen-Dechent, W., Tacke, F. (2015): Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease. *Hepatology* **63**(4), 1310-1324.
- [6] Gautheron, J.[#], **Vucur, M.**[#], Reisinger, F.[#], Cardenas, D. V., Roderburg, C., Koppe, C., Kreggenwinkel, K., Schneider, A. T., Bartneck, M., Neumann, U. P., Canbay, A., Reeves, H. L., Luedde, M., Tacke, F., Trautwein, C., Heikenwalder, M., Luedde, T. (2014): A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. *EMBO Mol Med*, **6**, 1062-1074. [#] equal contribution.
- [7] **Vucur, M.**[#], Reisinger, F.[#], Gautheron, J.[#], Janssen, J., Roderburg, C., Cardenas, D. V., Kreggenwinkel, K., Koppe, C., Hammerich, L., Hakem, R., Unger, K., Weber, A., Gassler, N., Luedde, M., Frey, N., Neumann, U. P., Tacke, F., Trautwein, C., Heikenwalder, M., Luedde, T. (2013): RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation. *Cell Rep*, **4**, 776-790. [#] equal contribution.
- [8] Schneider, C., Teufel, A., Yevsa, T., Staib, F., Hohmeyer, A., Walenda, G., Zimmermann, HW., **Vucur, M.**, Huss, S., Gassler, N., Wasmuth, HE., Lira, SA., Zender, L., Luedde, T., Trautwein, C., Tacke, F. (2012): Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. *Gut*, **61**, 1733-1743.
- [9] Kang, T.W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., Iken, M., **Vucur, M.**, Weiss, S., Heikenwalder, M., Khan, S., Gil, J., Bruder, D., Manns, M., Schirmacher, P., Tacke, F., Ott, M., Luedde, T., Longerich, T., Kubicka, S., Zender, L. (2011): Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. *Nature*, **479**, 547-551.
- [10] Bettermann, K.[#], **Vucur, M.**[#], Haybaeck, J., Koppe, C., Janssen, J., Heymann, F., Weber, A., Weiskirchen, R., Liedtke, C., Gassler, N., Muller, M., de Vos, R., Wolf, M. J., Boege, Y., Seleznik, G. M., Zeller, N., Ery, D., Fuchs, T., Zoller, S., Cairo, S., Buendia, M. A., Prinz, M., Akira, S., Tacke, F., Heikenwalder, M., Trautwein, C., Luedde, T. (2010): TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. *Cancer Cell*, **17**, 481-496. [#] equal contribution.

Wagner


1. General data

Wagner, Wolfgang, Univ.-Prof. Dr. med. Dr. rer. nat. *17.12.1973 (m)

Institute of Biomedical Engineering, Stem Cell Biology and Cellular Engineering
University Hospital Aachen, RWTH Aachen
Pauwelsstr. 20
D-52074 Aachen

Phone: ++49 (0)241-80 88611
Fax: ++49 (0)241-80 82008
E-mail: wwagner@ukaachen.de

University Professor (W2)



2. Scientific education

07/2008	Habilitation and <i>venia legendi</i> in Physiology, University of Heidelberg
2002 – 2005	PhD thesis, University of Heidelberg
2000 – 2002	MD thesis, University of Bonn
1995 - 2002	Studies in Medicine, University of Bonn (and Biel, Switzerland)
1993 - 1998	Studies in Biology, University of Bonn (and Norwich, UK)

3. Academic degrees

04/2009	Professor assignment, W2 for Stem Cell Biology and Cellular Engineering, Medical Faculty at RWTH Aachen University
07/2008	Habilitation and <i>venia legendi</i> in Physiology
2002 – 2005	PhD thesis (<i>magna cum laude</i>)
2000 – 2002	MD thesis (<i>magna cum laude</i>)
04/2002	Final medical examination
11/1998	Diploma in Biology (<i>summa cum laude</i>)

4. Scientific positions

Since 04/2014	Secondary affiliation at the Faculty of Mathematics, Computer Science and Natural Sciences, RWTH Aachen
Since 03/2014	Co-founder and a CEO of Cygenia GmbH; A company providing service for analysis of epigenetic biomarkers (www.cygenia.com)
Since 04/2009	University Professor at RWTH Aachen University Medical School (W2) at the Institute for Biomedical Engineering – Cell Biology (chair: Prof. Dr. M. Zenke); Head of the Department “Stem Cell Biology and Cellular Engineering”
2006 – 2009	Research fellowship at the Institute of Physiology and Pathophysiology, University of Heidelberg (chair: Prof. Dr. W. Kuschinsky) and at the Department of Medicine, Division of Hematology/Oncology, University of Heidelberg
2004 – 2006	Intern and research assistant at the Department of Medicine, Division of Hematology/Oncology, University of Heidelberg (chair: Prof. Dr. A. D. Ho)
2002 – 2004	Clinical fellowship at the Department of Medicine, Division of Hematology/Oncology, University of Heidelberg and post-doctoral fellow at the European Molecular Biology Laboratory (EMBL)

5. Other (function in editorial or advisory board, honours and awards)

Since 2017	Editor of <i>Scientific Reports</i>
Since 2015	Editor of <i>Clinical Epigenetics</i>
Since 2013	Editor of <i>PLoS ONE</i>
2016 – 2020	Extended board member of the German Stem Cell Network (GSCN)
2013 - 2018	Board of Directors of Euregional Cancer Centre Aachen
2013	Guest Editor at <i>Stem Cells International</i>
2013	Vision4 Life-Sciences Research Price for Regenerative Medicine (10,000€)
2007	Award of a young investigator research group by the Stem Cell Network NRW
2002	Price for the medical dissertation of the Heart-Center, University of Bonn (1,000€)

6. Most important publications

- [1] Franzen, J., Zirkel, A., Blake, J., Rath, B., Benes, V., Papantonis, A., **Wagner, W. (2017)**: Senescence-associated DNA methylation is stochastically acquired in subpopulations of mesenchymal stem cells. *Aging Cell*, **16**, 183-191.
- [2] Candio de Almeida, D., Ferreira, M. R., Franzen, J., Weidner, C., Frobel, J., Zenke, M., Costa, I. G., **Wagner, W. (2016)**: Epigenetic classification of human mesenchymal stromal cells. *Stem Cell Reports* **6**, 168-175.
- [3] Kalwa, M., Hänzelmann, S., Otto, S., Kuo, C. C., Franzen, J., Joussem, S., Fernandez-Rebollo, E., Rath B, Koch C, Hofmann A, Lee S. H., Teschendorff, A., Denecke, B., Lin, Q., Widschwendter, M., Weinhold, E., Costa, I., **Wagner W. (2016)**: The lncRNA HOTAIR impacts on mesenchymal stem cells via triple helix formation. *Nucl Acid Res*, **44**, 10631-10643.
- [4] Weidner, C. I., Ziegler, P., Hahn, M., Brümmendorf, T. H., Ho, A. D., Dreger, P., **Wagner, W. (2015)**: Epigenetic aging upon allogeneic transplantation: The hematopoietic niche does not affect age-associated DNA methylation. *Leukemia*, **4**, 985-988.
- [5] Lin, Q., **Wagner, W. (2015)**: Epigenetic aging signatures are coherently modified in cancer. *PLoS Genet*, **6**:e1005334.
- [6] Abagnale, G., Steger, M., Nguyen, V. H., Hersch, N., Sechi, A., Joussem, S., Denecke, B., Merkel, R., Hoffmann, B., Dreser, A., Schnakenberg, U., Gillner, A., **Wagner, W. (2015)**: Surface topography enhances differentiation of mesenchymal stem cells towards osteogenic and adipogenic lineages. *Biomaterials*, **61**, 316-26.
- [7] Weidner, C. I., Lin, Q., Koch, C. M., Eisele, L., Beier, F., Ziegler, P., Bauerschlag, D. O., Jöckel, K. H., Erbel, R., Mühleisen, T. W., Zenke, M., Brümmendorf, T. H., **Wagner, W. (2014)**: Aging of blood can be tracked by DNA methylation changes at just three CpG sites. *Genome Biol*, **15**:R24.
- [8] Jost, E., Lin, Q., Weidner, C. I., Wilop, S., Hoffmann, M., Walenda, T., Schemionek, M., Herrmann, O., Zenke, M., Brümmendorf, T., Koschmieder, S., **Wagner, W. (2014)**: Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia. *Leukemia***28**, 1227-1234.
- [9] Frobel, J., Hameda, H., Lenz, M., Abagnale, G., Joussem, S., Denecke, B., Šarić, T., Zenke, M., **Wagner, W. (2014)**: Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. *Stem Cell Reports*, **3**, 414-422.
- [10] Koch, C. M., Reck, K., Shao, K., Lin, Q., Ziegler, P., Joussem, S., Walenda, G., Drescher, W., Opalka, B., May, T., Brümmendorf, T., Zenke, M., Saric, T., **Wagner, W. (2013)**: Pluripotent stem cells escape from senescence-associated DNA methylation changes. *Genome Res*, **23**, 248-259.

Weiskirchen

1. General data

Weiskirchen, Ralf, Univ.-Prof. Dr. rer. nat. *02.02.1964 (m)

Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry
University Hospital Aachen, RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen

Phone: ++49 (0)241-80 88683
Fax: ++49 (0)241-80 3388683
E-mail: rweiskirchen@ukaachen.de



Director of the Institute, Professor (W2)

2. Scientific education

12/2001	Habilitation/ <i>Venia legendi</i> for Pathobiochemistry and Molecular Biology
1990 - 1994	PhD at the Institute of Biochemistry, University of Cologne
1988 - 1989	Diploma thesis at the Institute of Biochemistry, Faculty of Science, University of Cologne
1983 - 1989	Studies in Biology, University of Cologne

3. Academic degrees

07/2008	W2 for Molecular Pathobiochemistry & Exp. Gene Therapy, UKA
03/2007	apl Professor assignment
12/2001	Habilitation in Pathobiochemistry and Molecular Biology
04/1994	PhD thesis (<i>summa cum laude</i>) in Biology
08/1989	Diploma in Biology

4. Scientific positions

since 04/2014	Director of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry, UKA
08/2009 -03/2014	Acting Director of the Institute of Clinical Chemistry and Pathobiochemistry and Central Laboratory, UKA
since 07/2008	Assistant Professor (W2), RWTH University Hospital Aachen
04/1999 - 06/2008	Staff member (C1/C2), Institute of Clinical Chemistry and Pathobiochemistry, UKA (Director Prof. Dr. A. M. Gressner)
05/1994 - 03/1999	Staff member (Post-Doc), Institute of Biochemistry, Faculty of Science, University of Innsbruck, Austria (Director Prof. Dr. K. Bister)
1990 - 1994	Research assistant, Institute of Biochemistry, Medical Faculty, University of Cologne (Director Prof. Dr. Dr. W. Stoffel)
1989 - 1990	Civil service at the Institute of Clinical Chemistry, Medical Faculty, University Hospital of Cologne (Director Prof. Dr. K. Oette)
1988 - 1989	Student assistant at the Institute of Biochemistry, Faculty of Science, University of Cologne (Director Prof. Dr. Dr. L. Jaenicke)

Weiskirchen

5. Other (function in editorial or advisory board, honours and awards)

2015	Guest Editor Laboratory Animals, Guest Editor Frontiers Physiology
2014-2016	EASL Abstract Reviewing Panel Board
2014	Guest Editor Hepatobiliary Surgery and Nutrition
since 2011	Elected member of the Internal Advisory Board of the IZKF Aachen
since 2010	Scientific/Medical Advisory Board Morbus Osler Foundation, Germany
since 2010	Guest Associate Editor Frontiers in Gastrointestinal Sciences
since 2008	Associate Editor J. Cell. Biochem., Editorial Board Hepatitis Monthly
since 2007	Assignment as a Member of the Faculty 1000 in Medicine
2004	Speaker of the interdisciplinary research consortium "Identification of molecular markers and gene therapy of fibrosis and other wound healing processes" at the RWTH University Aachen
1998	Price of the state capital Innsbruck for the scientific activity at the Leopold-Franzens-University Innsbruck, Austria

6. Most important publications

- [1] Borkham-Kamphorst, E., Steffen, B. T., Van de Leur, E., Tihaa, L., Haas, U., Voitok, M. M., Meurer, S. K., Weiskirchen R. (2016): Adenoviral CCN gene transfers induce *in vitro* and *in vivo* endoplasmic reticulum stress and unfolded protein response. *Biochim Biophys Acta*, **1863**, 2604-2612.
- [2] Borkham-Kamphorst, E., Meurer, S. K., Van de Leur, E., Haas, U., Tihaa, L., **Weiskirchen, R.** (2015): PDGF-D signaling in portal myofibroblasts and hepatic stellate cells proves identical to PDGF-B via both PDGF receptor type α and β . *Cell Signal*, **27**, 1305-1314.
- [3] Boaru, S. G., Merle, U., Uerlings, R., Zimmermann, A., Flechtenmacher, C., Willheim, C., Eder, E., Ferenci, P., Stremmel, W., **Weiskirchen, R.** (2015): Laser ablation inductively coupled plasma mass spectrometry imaging of metals in experimental and clinical Wilson's disease. *J Cell Mol Med*, **19**, 806-814.
- [4] Asimakopoulou, A., Borkham-Kamphorst, E., Henning, M., Yagmur, E., Gassler, N., Liedtke, C., Berger, T., Mak, T. W., Weiskirchen, R. (2014): Lipocalin-2 (LCN2) regulates PLIN5 expression and intracellular lipid droplet formation in the liver. *Biochim Biophys Acta*, **1842**, 1513-1524.
- [5] Borkham-Kamphorst, E., Schaffrath, C., Van de Leur, E., Haas, U., Tihaa, L., Meurer, S. K., Nevzorova, Y. A., Liedtke, C., **Weiskirchen, R.** (2014): The anti-fibrotic effects of CCN1/CYR61 in primary portal MFB are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF- β signaling. *Biochim Biophys Acta*, **1843**, 902-914.
- [6] **Weiskirchen, R.**, Weimer, J., Meurer, S. K., Kron, A., Seipel, B., Vater, I., Arnold, N., Siebert, R., Xu, L., Friedman, S. L., Bergmann, C. (2013): Genetic characteristics of the human hepatic stellate cell line LX-2. *PLoS One*, **8**(10):e75692.
- [7] Dietzel, E., Wessling, J., Floehr, J., Schäfer, C., Ensslen, S., Denecke, B., Rösing, B., Neulen, J., Veitinger, T., Spehr, M., Tropartz, T., Tolba, R., Renné, T., Egert, A., Schorle, H., Gottenbusch, Y., Hildebrand, A., Yiallourou, I., Stöcker, W., **Weiskirchen, R.**, Jahnen-Dechent, W. (2013): Fetuin-B, a liver-derived plasma protein is essential for fertilization. *Dev Cell* **25**, 106-112.
- [8] Borkham-Kamphorst, E., van de Leur, E., Zimmermann, H. W., Karlmark, K. R., Tihaa, L., Haas, U., Tacke, F., Berger, T., Mak, T. W., **Weiskirchen, R.** (2013): Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis. *Biochim Biophys Acta*, **1832**, 660-673.
- [9] Borkham-Kamphorst, E., Zimmermann, H. W., Gassler, N., Bissels, U., Bosio, A., Tacke, F., **Weiskirchen, R.***, Kanse, S. M.* (2013): Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men. *J Hepatol*, **58**, 104-111.
- [10] Meurer, S. K., Vreden, W. N., Tihaa, L., **Weiskirchen, R.** (2011): Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. *Cell Signal*, **23**, 683-699.

Zenke


1. General data

Zenke, Martin, Univ.-Prof. Dr. rer. nat.

***07.08.1953 (m)**

Institute of Biomedical Engineering, Department of Cell Biology
University Hospital RWTH Aachen
Pauwelsstr. 30

Helmholtz Institute for Biomedical Engineering
RWTH Aachen University
Pauwelsstr. 20
52074 Aachen



Phone: ++49-241-80 80760
Fax: ++49-241-80 82008
E-mail: martin.zenke@rwth-aachen.de
Web page: <http://www.molcell.de>

Full Professor of Cell Biology, Chairman and Director (C4)

2. Scientific education

- | | |
|-------------|---|
| 1979 - 1982 | Graduate studies in Molecular and Cell Biology, Institute for Virus Research, German Cancer Research Center (DKFZ), Heidelberg, Germany |
| 1978 - 1979 | Diploma thesis, Institute of Chemistry and Biochemistry, Philipps-University, Marburg, Germany |
| 1972 - 1979 | Studies in Chemistry/Biochemistry and Medicine, Philipps-University, Marburg, Germany |

3. Academic degrees

- | | |
|------|--|
| 2003 | Full Professor of Cell Biology (C4) and Chairman, RWTH Aachen University, Aachen, Germany |
| 1992 | Lecture qualification (Habilitation) in Molecular Genetics, Faculty of Life Sciences, Vienna University, Vienna, Austria |
| 1982 | PhD, Faculty of Life Sciences, Ruprecht-Karls-University, Heidelberg, Germany |
| 1979 | Diploma in Chemistry/Biochemistry, Philipps-University, Marburg, Germany |

4. Scientific positions

- | | |
|-------------|--|
| since 2003 | Professor of Cell Biology (C4) and Chairman, Institute for Biomedical Engineering, Department of Cell Biology, RWTH Aachen University Medical School and Helmholtz Institute for Biomedical Engineering, RWTH, Aachen, Germany |
| 2011 - 2014 | Managing Director Helmholtz Institute for Biomedical Engineering (3 year term), RWTH Aachen University, Aachen, Germany |
| 1995 - 2003 | Research Group Leader (C3), Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany |
| 1988 - 1995 | Junior Scientist and Group Leader, Institute of Molecular Pathology (IMP), Vienna, Austria |

Zenke

1985 - 1988	EMBL Fellow and Staff Scientist, Differentiation Programme, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
1982 - 1985	Postdoctoral Fellow (DFG), LGME and Université Louis Pasteur, Faculté de Médecine, Strasbourg, France

5. Other (function in editorial or advisory board, honours and awards)

since 2014	Member of Editorial Board <i>Journal Biological Chemistry</i>
since 2013	Member of "Gene Technology Monitoring Program" of Berlin-Brandenburg Academy of Sciences and Humanities, Berlin
since 2010	Coordinator of <i>StemCellFactory</i> Consortium (www.stemcellfactory.de) (jointly with O. Brüstle, Life&Brain, Bonn)
since 2008	Member of "Central Ethics Committee for Stem Cell Research", Federal Ministry of Education and Research (BMBF) and Federal Ministry of Health (BMG), Berlin
2006-2012	Steering Committee DFG Priority Programme 1356 "Pluripotency and Cellular Reprogramming"
since 2004	Steering Committee "Stem Cell Network North Rhine-Westphalia", Düsseldorf

6. Most important publications

- [1] Sontag, S., Förster, M., Qin, J., Wanek, P., Mitzka, S., Schüler, H. M., Koschmieder, S., Rose-John, S., Seré, K., **Zenke, M. (2017)**: Modelling IRF8 deficient human hematopoiesis and dendritic cell development with engineered induced pluripotent stem cells. *Stem Cells*, **35**, 898-908.
- [2] Seré, K., Baek, J.-H., Ober-Blöbaum, J., Müller-Newen, G., Tacke, F., Yokota, Y., **Zenke, M.***, Hieronymus, T.* **(2012)**: Two distinct types of Langerhans cells populate the skin during steady state and inflammation. *Immunity*, **37**, 905-919. * Corresponding authors.
- [3] Kim, J. B., Sebastiano, V., Wu, G., Araúzo-Bravo, M. J., Sasse, P., Gentile, L., Ko, K., Ruau, D., Ehrich, M., van den Boom, D., Meyer, J., Hübner, K., Bernemann, C., Ortmeier, C., Zenke, M., Kim, J. B., Zaehres, H., Wu, G., Gentile, L., Sebastiano, V., Ko, K., Araúzo-Bravo, M. J., Ruau, D., Han, D. W., **Zenke, M.**, Schüler, H. R. **(2008)**: Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. *Nature*, **454**, 646-650.
- [4] Hacker, C., Kirsch, R. D., Ju, X.-S., Hieronymus, T., Gust, T. C., Kuhl, C., Jorgas, T., Kurz, S. M., Rose-John, S., Yokota, Y., **Zenke, M. (2003)**: Transcriptional profiling identifies Id2 function in dendritic cell development. *Nature Immunol.*, **4**, 380-386.
- [5] Panzenböck, B., Bartunek, P., Mapara, M., **Zenke, M. (1998)**: Growth and differentiation of human stem cell factor/erythropoietin-dependent erythroid progenitor cells *in vitro*. *Blood* **92**, 3658-3668.
- [6] Boehmelt, G., Madruga, J., Dörfler, P., Briegel, K., Schwarz, H., Enrietto, P., **Zenke, M. (1995)**: Dendritic cell progenitor is transformed by a conditional v-rel estrogen receptor fusion protein v-relER. *Cell*, **80**, 341-352.
- [7] **Zenke, M.**, Muñoz, A., Sap, J., Vennström, B., Beug, H. **(1990)**: v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbA. *Cell*, **61**, 1035-1049.
- [8] **Zenke, M.**, Kahn, P., Disela, C., Vennström, B., Leutz, A., Keegan, K., Hayman, M., Choi, H.R., Yew, N., Engel, D., and Beug, H. **(1988)**: v-erbA specifically suppresses transcription of the avian erythrocyte anion transporter (band 3) gene. *Cell*, **52**, 107-119.
- [9] Davidson, I., Fromental, C., Augereau, P., Wildeman, A.G., **Zenke, M.**, Chambon, P. **(1986)**: Cell-type specific protein binding to the enhancer of Simian Virus 40 in nuclear extracts. *Nature*, **323**, 544-548.
- [10] **Zenke, M.**, Grundström, T., Matthes, H., Wintzerith, M., Schatz, C., Wildeman, A. G., Chambon, P. **(1986)**: Multiple sequence motifs are involved in SV40 enhancer function. *EMBO J.*, **5**, 387-397.